#!/usr/bin/env python
# -*- coding: utf-8 -*-
# @Date  : 2025/7/25 17:12
# @File  : xml_convert_json.py
# @Author: johnson
# @Contact : github: johnson7788
# @Desc  : XML格式转换成json格式，方便ppt下载
import os
import re
import uuid
import requests
import json
import dotenv
import logging
import xml.etree.ElementTree as ET
from bs4 import BeautifulSoup
dotenv.load_dotenv()

logger = logging.getLogger(__name__)

def generate_ppt_xml_second():
    # page_number相同的会被替换
    first_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                          'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                     'final': False, 'kind': 'status-update', 'status': {
                                                  'message': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                              'kind': 'message',
                                                              'messageId': '45240995-70ba-44ef-9b05-26bfa0c25299',
                                                              'metadata': {'author': 'PPTWriterSubAgent', 'show': True,
                                                                           'references': [
                                                                               'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                               'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                               'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                               'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                               'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                               'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                               'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                               'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                               'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                               'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                               'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                               'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                               'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                               'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                               'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                               'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                               'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                               'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                               'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                               'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                               'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                               'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                               'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                               'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                               'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                               'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                               'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                               'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                               'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                               'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                               'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                               'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                               'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                               'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                               'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                               'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                               'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                               'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                               'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                               'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                               'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                               'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                               'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                               'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                               'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                               'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                               'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                               'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                               'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                               'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                               'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                               'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                               'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                               'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                               'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                               'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                               'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                               'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                               'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                               'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                               'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                               'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                               'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                               'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                               'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                               'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                               'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                               'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                               'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                               'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                               'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                               'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                               'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                               'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                               'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                               'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                               'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                               "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                               'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                               'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                               'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                               'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                               'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                               'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                               'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                               'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                               'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                               'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                               'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                               'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                               'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                               'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                               'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                               'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                               'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                               'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                               'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                               'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                               'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                               'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                               'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                               'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                               'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                               'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                               'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                               'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                               'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                               'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                               'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                               'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                               'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                               'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                               'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                               'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                               'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                               'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                               'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                               'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                               'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                               'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                               'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                               'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                               'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                               'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                               'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                               'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                               'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                               'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                               'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                               'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                               'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                               'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                               'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                               'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                               'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                               'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                               'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                               'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                               'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                              'parts': [
                                                                  {'kind': 'text', 'text': '```xml\n<PRESENTATION>\n'}],
                                                              'role': 'agent',
                                                              'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                  'state': 'working', 'timestamp': '2025-07-25T08:30:11.191221+00:00'},
                                                     'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}

    first_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0',
                                          'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90',
                                                     'final': False, 'kind': 'status-update', 'status': {
                                                  'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90',
                                                              'kind': 'message',
                                                              'messageId': '22d091ba-7f37-4864-bdab-18f6c45e6e1f',
                                                              'metadata': {'author': 'PPTWriterSubAgent', 'show': True,
                                                                           'references': [
                                                                               'Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533',
                                                                               'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365',
                                                                               'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718',
                                                                               'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417',
                                                                               'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059',
                                                                               'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429',
                                                                               'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720',
                                                                               'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174',
                                                                               'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633',
                                                                               'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256',
                                                                               'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348',
                                                                               'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250',
                                                                               'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880',
                                                                               'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055',
                                                                               'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1',
                                                                               'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671',
                                                                               'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356',
                                                                               'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222',
                                                                               'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896',
                                                                               'Probiotics, prebiotics and food allergy: a review -- PMID:38054607',
                                                                               'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931',
                                                                               'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510',
                                                                               'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196',
                                                                               'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673',
                                                                               'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936',
                                                                               '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1',
                                                                               'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233',
                                                                               'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094',
                                                                               'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493',
                                                                               'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412',
                                                                               'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556',
                                                                               '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785',
                                                                               'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542',
                                                                               'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768',
                                                                               'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456',
                                                                               'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597',
                                                                               'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975',
                                                                               'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247',
                                                                               'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427',
                                                                               'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230',
                                                                               'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000',
                                                                               'Post-intervention control in HIV immunotherapy trials -- PMID:39494630',
                                                                               'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161',
                                                                               'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422',
                                                                               'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638',
                                                                               'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885',
                                                                               'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359',
                                                                               'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998',
                                                                               'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326',
                                                                               'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508',
                                                                               'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927',
                                                                               'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998',
                                                                               'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646',
                                                                               'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081',
                                                                               'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389',
                                                                               'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949',
                                                                               'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489',
                                                                               'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994',
                                                                               'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718',
                                                                               'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859',
                                                                               'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258',
                                                                               'Engineered bacteria in tumor immunotherapy -- PMID:38492769',
                                                                               'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284',
                                                                               'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203',
                                                                               'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776',
                                                                               'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321',
                                                                               'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807',
                                                                               'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360',
                                                                               'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516',
                                                                               'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107',
                                                                               'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160',
                                                                               'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151',
                                                                               'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751',
                                                                               'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368',
                                                                               'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399',
                                                                               'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144',
                                                                               'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536',
                                                                               'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378',
                                                                               'The microbiome in pediatric oncology -- PMID:32533793',
                                                                               'Gut Microbiota and Immunotherapy -- PMID:35847121',
                                                                               'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044',
                                                                               'Short-chain fatty acids and cancer -- PMID:39638744',
                                                                               '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1',
                                                                               'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979',
                                                                               'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771',
                                                                               'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098',
                                                                               '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1',
                                                                               'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241',
                                                                               'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901',
                                                                               'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960',
                                                                               'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348',
                                                                               'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231',
                                                                               'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698',
                                                                               'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929',
                                                                               'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562',
                                                                               'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895',
                                                                               'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452',
                                                                               'Gut microbial metabolites in cancer therapy -- PMID:39004537',
                                                                               'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456',
                                                                               'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']},
                                                              'parts': [{'kind': 'text',
                                                                         'text': '```xml\n<!-- 第1页开始-->\n<SECTION layout="vertical" page_number=1>\n  <H1>肠道菌群与癌症免疫治疗：一个 evolving paradigm</H1>\n\n  <BULLETS>\n    <DIV><H3>核心概念</H3><P>肠道菌群通过调节局部与全身免疫稳态，深刻影响肿瘤进展和免疫治疗响应差异</P></DIV>\n    <DIV><P>免疫检查点抑制剂（ICIs）疗效个体差异显著，近年研究证实肠道菌群是关键决定因素</P></DIV>\n    <DIV><P>多组学整合、标准化临床流程与靶向干预代表精准免疫肿瘤学的新前沿</P></DIV>\n  </BULLETS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background1.jpg" alt="背景图：肠道菌群-免疫-肿瘤轴示意图" background="true" />\n</SECTION>\n<!-- 第1页结束-->\n```'}],
                                                              'role': 'agent',
                                                              'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'},
                                                  'state': 'working', 'timestamp': '2025-07-30T03:40:51.734353+00:00'},
                                                     'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    second_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': '13a54f3a-ebf3-41c5-91e5-4ebed5596598', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '<!-- 第2页开始-->\n<SECTION layout="vertical" page_number=2>\n  <H1>机制解析：肠道菌群如何塑造免疫治疗结局</H1>\n\n  <BULLETS>\n    <DIV><H3>调节肿瘤微环境（TME）</H3><P>通过代谢物与免疫细胞互作，重塑局部抗肿瘤免疫状态，决定“冷”或“热”型肿瘤表型</P></DIV>\n    <DIV><P>短链脂肪酸（SCFAs）促进M1巨噬细胞极化、增强CD8+ T细胞浸润；而色氨酸衍生物激活AhR通路可诱导髓系免疫抑制</P></DIV>\n    <DIV><P>菌群失调导致促炎/免疫抑制微环境，削弱ICIs疗效；细菌细胞壁成分（如LPS、肽聚糖）通过PRRs放大或限制抗肿瘤反应</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>关键代谢物作用机制</H3>\n      <BULLETS>\n        <DIV><P>SCFAs → GPCR + HDAC抑制 → 抗炎 & T细胞活化</P></DIV>\n        <DIV><P>色氨酸代谢物 → AhR激活 → 免疫耐受 / 肿瘤逃逸</P></DIV>\n        <DIV><P>胆汁酸 → FXR/TGR5信号 → 平衡Treg/Th17比例</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>临床转化潜力</H3>\n      <BULLETS>\n        <DIV><P>靶向调控这些代谢通路（如补充butyrate、阻断AhR）有望逆转免疫耐药</P></DIV>\n        <DIV><P>人工智能整合多组学数据，预测个体对特定代谢干预的响应</P></DIV>\n        <DIV><P>未来方向：开发基于菌群-代谢网络的精准免疫协同策略</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://img.infox-med.com/images/35139348/6f0b0a9c5f8d55d3e6417e108a39f5b49896453f1255601965622108f36e8f1e.jpg" alt="微生物代谢物对肿瘤微环境免疫表型的影响示意图" background="false" />\n</SECTION>\n<!-- 第2页结束-->'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:41:01.125759+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    third_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': '21749e06-2772-45db-ba1d-4d5b42cd4334', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '<!-- 第3页开始-->\n<SECTION layout="vertical" page_number=3>\n  <H1>临床证据：肠道菌群与免疫治疗疗效</H1>\n\n  <BULLETS>\n    <DIV><H3>关键发现：响应者 vs 非响应者菌群差异</H3>\n      <P>黑色素瘤患者中，应答者富集Akkermansia、Bifidobacterium和Roseburia；非应答者则以Barnesiella和低多样性为主</P>\n      <P>非小细胞肺癌（NSCLC）中，应答者表现为Escherichia-Shigella、Akkermansia升高，Streptococcus减少</P>\n    </DIV>\n    <DIV><H3>微生物标志物预测价值</H3>\n      <P>Akkermansia muciniphila、Ruminococcus torques等已被证实为潜在生物标志物，联合TIGIT+ NK细胞可提升预测准确性（AUC ~0.85）</P>\n      <P>代谢物如吡咯啉（Pyrrolidine）在胆道癌中也显示出阳性关联</P>\n    </DIV>\n    <DIV><H3>抗生素使用显著削弱疗效</H3>\n      <P>治疗前或期间使用广谱抗生素（如氟喹诺酮类）会降低ICIs疗效和生存率，尤其在黑色素瘤中风险最高</P>\n      <P>机制可能涉及有益菌群耗竭及免疫微环境重塑失败</P>\n    </DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>粪菌移植（FMT）临床转化</H3>\n      <BULLETS>\n        <DIV><P>将ICI应答者的粪便菌群移植给难治性黑色素瘤患者，约30–44%实现客观缓解</P></DIV>\n        <DIV><P>机制包括：供体菌定植、T细胞浸润增强、肿瘤微环境重编程</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>未来方向：精准干预策略</H3>\n      <BULLETS>\n        <DIV><P>开发基于菌群功能的“数字肠道双胞胎”模型，用于个体化分层管理</P></DIV>\n        <DIV><P>结合膳食干预（高纤维）、益生元/益生菌组合，构建多维微生态调控体系</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://img.infox-med.com/images/37692859/27f5d7d4ad276c8616294cba886d6604ad1c4082b6a2d8a77bb3964536af1987.jpg" alt="应答者与非应答者菌群组成差异及生存曲线对比图" background="false" />\n</SECTION>\n<!-- 第3页结束-->'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:41:13.629572+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    forth_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'ee3bfdb4-c773-46f3-a89a-70c3dcf25c8d', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '<!-- 第4页开始-->\n<SECTION layout="vertical" page_number=4>\n  <H1>Modulating Gut Microbiota for Immunotherapy Success</H1>\n\n  <BULLETS>\n    <DIV><H3>核心策略：四大干预手段协同优化菌群</H3></DIV>\n    <DIV><P>通过益生菌、饮食调控、粪菌移植（FMT）和工程菌等手段，靶向重塑肠道微生态，增强免疫治疗响应率</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>1. 益生菌与益生元</H3>\n      <BULLETS>\n        <DIV><P>补充特定菌株（如Bifidobacterium、Akkermansia）可促进T细胞浸润与抗炎环境形成</P></DIV>\n        <DIV><P>高纤维饮食刺激SCFA产生，改善肿瘤微环境并提升ICI疗效（临床试验NCT04645680正在进行中）</P></DIV>\n        <DIV><P>⚠️ 注意：市售益生菌产品可能因菌株不明确或低膳食纤维配合反而削弱疗效</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>2. 粪菌移植（FMT）</H3>\n      <BULLETS>\n        <DIV><P>将ICI应答者粪便菌群移植给难治性黑色素瘤患者，约30–44%实现客观缓解</P></DIV>\n        <DIV><P>机制包括供体菌定植、T细胞活化增强及免疫抑制微环境重编程</P></DIV>\n        <DIV><P>当前挑战：标准化 donor筛选、长期安全性评估、多中心推广可行性</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>3. 工程化微生物</H3>\n      <BULLETS>\n        <DIV><P>设计具备靶向递送能力的“智能细菌”——在肿瘤部位释放免疫激动剂或代谢物</P></DIV>\n        <DIV><P>已在动物模型中验证其增强PD-1阻断效果的能力，且具副作用自毁机制</P></DIV>\n        <DIV><P>未来方向：构建合成菌群 consortia，替代传统FMT，提高疗效一致性与可控性</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>4. 菌群功能导向的个性化干预</H3>\n      <BULLETS>\n        <DIV><P>结合AI建模与多组学数据，建立“数字肠道双胞胎”预测个体对不同干预的响应</P></DIV>\n        <DIV><P>推动从“广谱调节”向“精准定制”转变，实现微生态治疗的个体化分层管理</P></DIV>\n        <DIV><P>国际指南已开始探索将其纳入辅助治疗流程，尤其适用于耐药或毒副反应高风险人群</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://img.infox-med.com/images/35235771/a96a544e2cab592d22572dea9295607cae112529963b357b2304f2a47fba10f3.jpg" alt="高纤维饮食改善ICIs响应；商业益生菌可能降低晚期黑色素瘤疗效对比图" background="false" />\n</SECTION>\n<!-- 第4页结束-->'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:41:27.774305+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    forth_page_xml_second = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'c47f09b4-4250-47d2-bea9-e15d3ed791cd', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '<!-- 第4页开始-->\n<SECTION layout="vertical" page_number=4>\n  <H1>肠道菌群调控策略：优化免疫治疗响应的关键路径</H1>\n\n  <BULLETS>\n    <DIV><H3>核心目标</H3><P>通过靶向干预肠道菌群，重塑抗肿瘤免疫微环境，提升免疫检查点抑制剂（ICIs）疗效与安全性</P></DIV>\n    <DIV><P>当前主流策略包括益生菌/益生元、高纤维饮食、粪菌移植（FMT）及工程菌设计，各有优势与挑战</P></DIV>\n    <DIV><P>未来方向聚焦于个体化微生态干预方案，结合多组学分析与人工智能预测模型，实现精准免疫协同</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>干预方式对比</H3>\n      <BULLETS>\n        <DIV><P><strong>益生菌与益生元：</strong>非侵入性强，易推广；但效果依赖菌株特异性与膳食基础，市售产品需谨慎选择</P></DIV>\n        <DIV><P><strong>高纤维饮食：</strong>天然安全，促进SCFA生成；临床试验证实可增强ICI反应率，适合长期管理</P></DIV>\n        <DIV><P><strong>FMT：</strong>转化潜力大，已见客观缓解率30–44%；但存在供体筛选、标准化难题与潜在风险</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>新兴技术前沿</H3>\n      <BULLETS>\n        <DIV><P><strong>工程菌疗法：</strong>可编程微生物定点释放免疫激活因子，已在动物模型中验证抗肿瘤效应，正进入早期临床试验</P></DIV>\n        <DIV><P><strong>数字肠道双胞胎：</strong>基于AI整合患者菌群+代谢组+免疫特征，构建个性化干预模型，助力疗效预判与动态调整治疗</P></DIV>\n        <DIV><P><strong>精准FMT配方：</strong>由功能型菌群组合构成标准制剂，避免传统FMT变异问题，推动规范化应用</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <ARROWS>\n    <DIV><H3>从机制到临床：干预路径演进</H3><P>微生物代谢物→免疫细胞功能重塑→肿瘤微环境“冷转热”→ICI疗效提升</P></DIV>\n    <DIV><P>多维度联合干预（饮食+益生元+工程菌）将成为未来趋势，打破单一手段局限性</P></DIV>\n    <DIV><P>伦理、监管与标准化体系亟待完善，确保微生态治疗的安全性和可及性</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://img.infox-med.com/images/35235771/a96a544e2cab592d22572dea9295607cae112529963b357b2304f2a47fba10f3.jpg" alt="高纤维饮食改善免疫治疗响应 vs 商业益生菌可能降低疗效的对比图" background="false" />\n</SECTION>\n<!-- 第4页结束-->'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:41:43.162402+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    five_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'e912013d-d602-443e-9e04-9fe92fff182b', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '<!-- 第5页开始-->\n<SECTION layout="vertical" page_number=5>\n  <H1>未来展望：迈向精准的菌群靶向治疗</H1>\n\n  <BULLETS>\n    <DIV><H3>核心挑战</H3>\n      <P>标准化不足、个性化差异大、伦理与安全风险、多组学整合复杂性，仍是临床转化的关键瓶颈</P>\n    </DIV>\n    <DIV><P>当前菌群干预策略（如FMT、益生菌）存在供体变异、疗效不稳定、监管滞后等问题，亟需系统性解决方案</P></DIV>\n    <DIV><P>AI驱动的“数字肠道双胞胎”模型正在从概念走向实践，成为连接个体菌群特征与精准免疫协同的核心工具</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>标准化：临床落地的第一步</H3>\n      <BULLETS>\n        <DIV><P>统一样本采集、测序平台、生物信息分析流程，提升跨中心研究可比性</P></DIV>\n        <DIV><P>建立全球共识的微生物功能标志物体系（如SCFA产量、AhR激活能力），替代单纯物种丰度</P></DIV>\n        <DIV><P>推动“菌群制剂”注册标准制定，确保质量可控、安全性可评估</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>个性化：从群体到个体的跃迁</H3>\n      <BULLETS>\n        <DIV><P>基于患者菌群-代谢-免疫多维数据构建个体化干预模型（数字孪生体）</P></DIV>\n        <DIV><P>结合膳食、运动、抗生素管理等环境因素，实现动态微生态调控</P></DIV>\n        <DIV><P>开发可编程工程菌，定点释放免疫调节因子，实现“按需激活”而非泛化刺激</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <ARROWS>\n    <DIV><H3>伦理与监管：不可忽视的基石</H3><P>知情同意需涵盖长期菌群变化风险；数据隐私保护应纳入临床研究规范</P></DIV>\n    <DIV><P>公平获取机制保障低收入地区也能受益于先进疗法，避免“菌群鸿沟”扩大</P></DIV>\n    <DIV><P>建立国际协作框架，推动菌群治疗的全球监管互认与伦理指南更新</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://img.infox-med.com/images/35227509/6a4f8c4e6d8e5b48f5a6937a55227382b2526e14425535190a1847f55f7a482a.jpg" alt="菌群治疗临床转化路径中的标准化、个性化与伦理挑战示意图" background="false" />\n</SECTION>\n<!-- 第5页结束-->'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:41:55.152043+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    five_page_xml_second = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'c4d2ea8d-99e6-4097-a3a9-2b8e6115dfa2', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '```xml\n<!-- 第6页开始-->\n<SECTION layout="vertical" page_number=6>\n  <H1>结论：整合微生物组科学进入癌症免疫治疗</H1>\n\n  <BULLETS>\n    <DIV><H3>核心总结</H3><P>当前证据明确表明，肠道菌群通过调节免疫微环境、代谢通路和宿主反应，深刻影响免疫检查点抑制剂（ICIs）的疗效与安全性。</P></DIV>\n    <DIV><P>从机制解析到临床转化，多组学整合、标准化流程与靶向干预策略正在推动精准免疫肿瘤学迈向个体化新时代。</P></DIV>\n    <DIV><P>未来成功的关键在于跨学科协作——微生物学家、肿瘤学家、AI专家、伦理学家与监管机构需共同构建可重复、安全且公平的微生态治疗体系。</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV>\n      <H3>关键进展与挑战</H3>\n      <BULLETS>\n        <DIV><P>✅ 已实现：FMT改善难治性黑色素瘤响应率（30–44%）；益生菌/高纤维饮食提升ICI疗效；Akkermansia等标志物用于预判反应</P></DIV>\n        <DIV><P>⚠️ 待突破：菌群功能标准化、个性化干预模型验证、长期安全性与伦理框架建立</P></DIV>\n        <DIV><P>🚀 新方向：工程菌疗法、数字肠道双胞胎、AI驱动的多组学预测系统成为下一代精准免疫协同的核心工具</P></DIV>\n      </BULLETS>\n    </DIV>\n    <DIV>\n      <H3>行动呼吁：迈向多学科合作</H3>\n      <BULLETS>\n        <DIV><P>建立全球共识的菌群功能标志物体系（非单纯物种丰度），替代传统生物标志物</P></DIV>\n        <DIV><P>推动“菌群制剂”注册标准制定，确保质量可控、安全性可评估</P></DIV>\n        <DIV><P>倡导“微生物组感知用药”原则（pharmacomicrobiomics stewardship），减少抗生素滥用对免疫疗效的破坏</P></DIV>\n      </BULLETS>\n    </DIV>\n  </COLUMNS>\n\n  <ARROWS>\n    <DIV><H3>从发现到应用：一条不可逆的转化路径</H3><P>机制→生物标志物→干预策略→临床验证→规范推广</P></DIV>\n    <DIV><P>只有通过多中心研究、AI建模与患者分层管理，才能将菌群科学真正转化为普惠、高效的肿瘤免疫新范式</P></DIV>\n    <DIV><P>我们正站在一个时代转折点：让每一名癌症患者都能因自己的肠道菌群而获得更优的免疫治疗结局</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="背景图：肠道菌群-免疫-肿瘤轴示意图，象征未来精准免疫治疗愿景" background="true" />\n</SECTION>\n<!-- 第6页结束-->\n```'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:42:07.582492+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    six_page_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'd17d0419-9afd-4a5a-8aa4-4ab28047b9f2', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '```xml\n<!-- 第6页开始-->\n<SECTION layout="vertical" page_number=6>\n  <H1>结论：整合微生物组科学进入癌症免疫治疗</H1>\n\n  <BULLETS>\n    <DIV><H3>核心总结</H3>\n      <P>肠道菌群通过调节肿瘤微环境、免疫细胞功能和代谢通路，显著影响免疫检查点抑制剂（ICIs）的疗效与毒性反应。</P>\n      <P>当前研究已明确关键菌属（如Akkermansia、Bifidobacterium）、代谢物（SCFAs、色氨酸衍生物）及干预策略（FMT、高纤维饮食、工程菌）在提升免疫治疗响应中的作用。</P>\n    </DIV>\n    <DIV><H3>转化机遇</H3>\n      <P>开发基于菌群功能标志物的预测模型（如“数字肠道双胞胎”），推动个体化微生态干预成为精准免疫肿瘤学的新支柱。</P>\n      <P>多组学整合分析（基因组+代谢组+免疫组）将实现从机制解析到临床决策的闭环管理。</P>\n    </DIV>\n    <DIV><H3>未来方向：跨学科协作</H3>\n      <P>需建立全球标准化流程（样本采集、测序、数据分析），破解菌群干预的可重复性难题。</P>\n      <P>伦理监管体系应同步完善，确保微生态治疗的安全、公平与可及，避免“菌群鸿沟”扩大。</P>\n    </DIV>\n  </BULLETS>\n\n  <ARROWS>\n    <DIV><H3>从基础发现到临床落地</H3><P>微生物机制 → 生物标志物 → 干预策略 → 多中心验证 → 指南推荐</P></DIV>\n    <DIV><P>唯有跨学科合作（微生物学家、肿瘤医生、AI工程师、伦理学家）才能实现这一宏伟目标。</P></DIV>\n    <DIV><P>这不仅是科学突破，更是人类迈向个性化健康新时代的关键一步。</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="背景图：多学科协作推动精准免疫肿瘤学发展" background="true" />\n</SECTION>\n<!-- 第6页结束-->\n```'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:42:17.893947+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    end_xml = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'feec88af-e25e-4343-a57b-2ab129a56f4e', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:42:07.597181+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    six_page_xml_second = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': '605b68c3-6e91-47cc-9d3d-610a7ddcf491', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '```xml\n<!-- 第6页开始-->\n<SECTION layout="vertical" page_number=6>\n  <H1>结论：整合微生物组科学进入癌症免疫治疗</H1>\n\n  <BULLETS>\n    <DIV><H3>核心总结</H3>\n      <P>肠道菌群通过调节肿瘤微环境、免疫细胞功能和代谢通路，显著影响免疫检查点抑制剂（ICIs）的疗效与毒性反应。</P>\n      <P>当前研究已明确关键菌属（如Akkermansia、Bifidobacterium）、代谢物（SCFAs、色氨酸衍生物）及干预策略（FMT、高纤维饮食、工程菌）在提升免疫治疗响应中的作用。</P>\n    </DIV>\n    <DIV><H3>转化机遇</H3>\n      <P>开发基于菌群功能标志物的预测模型（如“数字肠道双胞胎”），推动个体化微生态干预成为精准免疫肿瘤学的新支柱。</P>\n      <P>多组学整合分析（基因组+代谢组+免疫组）将实现从机制解析到临床决策的闭环管理。</P>\n    </DIV>\n    <DIV><H3>未来方向：跨学科协作</H3>\n      <P>需建立全球标准化流程（样本采集、测序、数据分析），破解菌群干预的可重复性难题。</P>\n      <P>伦理监管体系应同步完善，确保微生态治疗的安全、公平与可及，避免“菌群鸿沟”扩大。</P>\n    </DIV>\n  </BULLETS>\n\n  <ARROWS>\n    <DIV><H3>从基础发现到临床落地</H3><P>微生物机制 → 生物标志物 → 干预策略 → 多中心验证 → 指南推荐</P></DIV>\n    <DIV><P>唯有跨学科合作（微生物学家、肿瘤医生、AI工程师、伦理学家）才能实现这一宏伟目标。</P></DIV>\n    <DIV><P>这不仅是科学突破，更是人类迈向个性化健康新时代的关键一步。</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="背景图：多学科协作推动精准免疫肿瘤学发展" background="true" />\n</SECTION>\n<!-- 第6页结束-->\n```'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:42:18.395528+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    end_xml_second = {'type': 'data', 'text': {'id': '3345f77951d148dbb3b0e5bbd62bb5c5', 'jsonrpc': '2.0', 'result': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '0f50f741-9831-497d-9931-2b1294db5e90', 'kind': 'message', 'messageId': 'feec88af-e25e-4343-a57b-2ab129a56f4e', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': ['Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy -- PMID:40617533', 'Crosstalk between Gut Microbiota and Cancer Immunotherapy: Present Investigations and Future Perspective -- PMID:39850365', 'Inflammatory bowel disease: The role of commensal microbiome in immune regulation -- PMID:34543718', 'M1 macrophage-related gene model for NSCLC immunotherapy response prediction -- PMID:38379417', 'Engineered bacteria recycle tumor metabolic waste to boost immunotherapy -- PMID:34883059', 'Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer -- PMID:34162429', 'Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota -- PMID:40185720', 'Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy -- PMID:38794174', 'Morphologic and Immunophenotypic Characterization of Conventional FLCN-Mutated Tumors (FMT) Compared to a Series of 8 Non-Conventional FMT -- PMID:40412633', 'Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review -- PMID:38594256', 'Immune sensing of microbial metabolites: Action at the tumor -- PMID:35139348', 'Gut microbiota and immune alteration in cancer development: implication for immunotherapy -- PMID:39944250', 'Impact of intestinal dysbiosis on breast cancer metastasis and progression -- PMID:36419880', 'Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology -- PMID:37003055', 'Research专题|聚焦肠道菌群在宿主健康与疾病中的新潜能 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=ir4C7iabonUigsKYQX0yeeu*C839SG5wwIXYX9Z2tJSYvC6dO4R5PqjctL1juXzMCdKmW*WI7QY4BsykLa0tQjEeRAx2ksKbnwacPeaiHttGGW6H6hmdY7xd0OwlxzZe&new=1', 'Adjuvant role of probiotics in allergen-specific immunotherapy -- PMID:36244671', 'Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies -- PMID:40023356', 'Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond -- PMID:36861222', 'Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy -- PMID:40530896', 'Probiotics, prebiotics and food allergy: a review -- PMID:38054607', 'Ultrasound-visible engineered bacteria for tumor chemo-immunotherapy -- PMID:38640931', 'Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies -- PMID:38868510', 'Critical role of the gut microbiota in immune responses and cancer immunotherapy -- PMID:38745196', 'How to Apply FMT More Effectively, Conveniently and Flexible - A Comparison of FMT Methods -- PMID:34150673', 'Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer -- PMID:38361936', '【专家论坛】肠道菌群移植对菌-肠-脑轴疾病的治疗研究进展 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846735&ver=6143&signature=mYjzVsBdod-OadRPUqUDcWhl1ArzLgRI6M-rgQCavw91cRouelPFQxnYH9tXH3GMa4nOCB8ZMEnjQh3Qy-yNWkQBiv49mOhjkLozAAXrLwuFNhs2CDRzqBpokNvk2-73&new=1', 'Microbial metabolites affect tumor progression, immunity and therapy prediction by reshaping the tumor microenvironment (Review) -- PMID:38847233', 'Preventing Colorectal Cancer through Prebiotics -- PMID:34207094', 'Potential role of the intratumoral microbiota in colorectal cancer immunotherapy -- PMID:38909493', 'The intriguing possibility of using probiotics in allergen-specific immunotherapy -- PMID:36852412', 'Short-chain fatty acids reverses gut microbiota dysbiosis-promoted progression of glioblastoma by up-regulating M1 polarization in the tumor microenvironment -- PMID:39159556', '[Gut Microbiota and Tumor Immune Microenvironment] -- PMID:34521785', 'Microbial metabolites and immunotherapy: Basic rationale and clinical indications -- PMID:36989542', 'Interaction between gut microbiota and immune checkpoint inhibitor-related colitis -- PMID:36389768', 'Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer -- PMID:39050456', 'Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy -- PMID:34229597', 'Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy -- PMID:38241975', 'Bacterial Keystone Taxa Regulate Carbon Metabolism in the Earthworm Gut -- PMID:35972247', 'Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy -- PMID:34589427', 'Gut Microbiota in Cancer Immune Response and Immunotherapy -- PMID:33674230', 'Nervous system-gut microbiota-immune system axis: future directions for preventing tumor -- PMID:40376000', 'Post-intervention control in HIV immunotherapy trials -- PMID:39494630', 'Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis -- PMID:38969161', 'A Special Network Comprised of Macrophages, Epithelial Cells, and Gut Microbiota for Gut Homeostasis -- PMID:35053422', 'The Divergent Immunomodulatory Effects of Short Chain Fatty Acids and Medium Chain Fatty Acids -- PMID:34208638', 'Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) -- PMID:38791885', 'Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer -- PMID:36426359', 'Dietary impacts on prostate cancer immunotherapy -- PMID:40437998', 'Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer -- PMID:36575326', 'Nanomaterial combined engineered bacteria for intelligent tumor immunotherapy -- PMID:39225508', 'A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: fecal microbiota transplantation -- PMID:38838927', 'Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways -- PMID:34221998', 'Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study -- PMID:39898646', 'Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light -- PMID:36279081', 'TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients -- PMID:38017389', 'Microbial metabolites are involved in tumorigenesis and development by regulating immune responses -- PMID:38169949', 'Intestinal Microbiome Modulation of Therapeutic Efficacy of Cancer Immunotherapy -- PMID:40348489', 'Unveiling the Health Benefits of Prebiotics: A Comprehensive Review -- PMID:39010994', 'Fecal transplantation in patient with metastatic melanoma refractory to immunotherapy: A case report -- PMID:37727718', 'Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review -- PMID:37692859', 'Gut Microbiota Dysbiosis Drives the Development of Colorectal Cancer -- PMID:32932258', 'Engineered bacteria in tumor immunotherapy -- PMID:38492769', 'The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy -- PMID:39645284', 'Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota -- PMID:34664203', 'Fecal Microbiota Transplantation for Immune Regulation: Improving Ulcerative Colitis and Enhancing Cancer Immunotherapy -- PMID:40592776', 'Diet and Immune Effects Trial (DIET)- a randomized, double-blinded dietary intervention study in patients with melanoma receiving immunotherapy -- PMID:39633321', 'Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review) -- PMID:38249807', 'An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome -- PMID:38717360', 'Novel and emerging prebiotics: Advances and opportunities -- PMID:33745516', 'Gut microbiota shapes cancer immunotherapy responses -- PMID:40715107', 'Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells -- PMID:32491160', 'Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease -- PMID:34646151', 'Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma -- PMID:35228751', 'Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer -- PMID:38831368', 'Gut Microbiota-MicroRNA Interactions in Intestinal Homeostasis and Cancer Development -- PMID:36677399', 'Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy -- PMID:36982144', 'Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer -- PMID:35988536', 'Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review -- PMID:37640378', 'The microbiome in pediatric oncology -- PMID:32533793', 'Gut Microbiota and Immunotherapy -- PMID:35847121', 'Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC -- PMID:36831044', 'Short-chain fatty acids and cancer -- PMID:39638744', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846712&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWz4NNTU9*AVNXGU7py51e9O9pqHDfepXhqFcnBC8GtYQI9lUe3g4J-QiU9xTebgbU&new=1', 'Gut Microbiota-Related Biomarkers in Immuno-Oncology -- PMID:39259979', 'Modulation of cancer immunotherapy by dietary fibers and over-the-counter probiotics -- PMID:35235771', 'Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials -- PMID:32607098', '2024-2025全球肠道菌群研究十大人物 | 《热心肠日报》年度榜单 -- https://mp.weixin.qq.com/s?src=11&timestamp=1753846670&ver=6143&signature=iX2HE38Jqtj-Ci7EtyBzLishSDAIq1BGaMAs8v7fqDutmliPtY5Ji8SyCMY6CwRWvr0et65SebrsYZmmTxQ2aq5ObH85M754M4TWnc0EJkPX5PPi7b1YuuFLrTxBPYGA&new=1', 'Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy -- PMID:39351241', 'Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. -- PMID:-41901', 'Engineered bacteria: Strategies and applications in cancer immunotherapy -- PMID:40528960', 'Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy -- PMID:37261348', 'Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors -- PMID:37488231', 'Bacterial abundant taxa exhibit stronger environmental adaption than rare taxa in the Arctic Ocean sediments -- PMID:38943698', 'Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis -- PMID:36899929', 'Predictive biomarkers of colon cancer immunotherapy: Present and future -- PMID:36483562', 'Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy -- PMID:36072895', 'Immuno-oncology-microbiome axis of gastrointestinal malignancy -- PMID:37275452', 'Gut microbial metabolites in cancer therapy -- PMID:39004537', 'Influence of gut microbial metabolites on tumor immunotherapy: mechanisms and potential natural products -- PMID:40066456', 'Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy -- PMID:36358736']}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}, 'state': 'working', 'timestamp': '2025-07-30T03:42:07.597181+00:00'}, 'taskId': '8e436678-d3ae-45a2-9e9a-c7c7ee95df72'}}}
    Stream = [first_xml, first_page_xml, second_page_xml, third_page_xml,forth_page_xml,forth_page_xml_second,five_page_xml,five_page_xml_second,six_page_xml,end_xml,six_page_xml_second, end_xml_second]
    # 用于存储每个页码对应的XML内容，键为页码，值为XML字符串
    page_xml_map = {}

    # 用于存储 <PRESENTATION> 和 </PRESENTATION> 这类非页码部分的XML
    overall_start_xml = ""
    overall_end_xml = ""

    # 存储最新的references
    latest_references = []

    # 正则表达式用于从 <SECTION> 标签中提取 page_number 属性
    # pattern = re.compile(r'<SECTION[^>]*page_number=(\d+)[^>]*>')
    # 改进的正则表达式，以匹配 page_number="1" 或 page_number=1 等多种情况
    # 同时确保只匹配 <SECTION ...> 标签中的 page_number
    # [^>]* 匹配除了 > 之外的任何字符，0次或多次
    # page_number=(\d+|"\d+") 匹配 page_number=数字 或 page_number="数字"
    page_number_pattern = re.compile(r'<SECTION[^>]+page_number\s*=\s*["\']?(\d+)["\']?[^>]*>')

    for one in Stream:
        # 提取 XML 文本内容
        content_parts = one["text"]["result"]["status"]["message"]["parts"]
        text_content = content_parts[0]["text"]

        # --- 移除 Markdown XML block 分隔符 ---
        start_delimiter = "```xml\n"
        end_delimiter = "```"
        if text_content.startswith(start_delimiter):
            text_content = text_content[len(start_delimiter):]
        if text_content.endswith(end_delimiter):
            text_content = text_content[:-len(end_delimiter)]

        # 移除 XML 注释行，例如 <!-- 第1页开始-->
        text_content = re.sub(r'<!--.*?-->\n?', '', text_content)

        # 更新 references，始终保留最新的
        latest_references = one["text"]["result"]["status"]["message"]["metadata"]["references"]

        # 尝试匹配 page_number
        match = page_number_pattern.search(text_content)

        if match:
            # 如果找到 page_number，则将其作为键存储，值是整个 SECTION 块的 XML
            page_number = int(match.group(1))
            page_xml_map[page_number] = text_content.strip()  # .strip() 移除多余的空白行
        elif text_content.strip() == '<PRESENTATION>':
            overall_start_xml = text_content.strip()
        elif text_content.strip() == '</PRESENTATION>':
            overall_end_xml = text_content.strip()

    # 按照页码顺序拼接最终的 XML 内容
    final_xml_parts = []

    if overall_start_xml:
        final_xml_parts.append(overall_start_xml)

    # 获取所有页码，并进行排序
    sorted_page_numbers = sorted(page_xml_map.keys())

    for page_num in sorted_page_numbers:
        final_xml_parts.append(page_xml_map[page_num])

    if overall_end_xml:
        final_xml_parts.append(overall_end_xml)

    PPT_content = "\n".join(final_xml_parts)  # 使用换行符连接各部分，保持可读性

    return PPT_content, latest_references

def generate_ppt_xml():
    # page_number相同的会被替换
    first_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                          'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                     'final': False, 'kind': 'status-update', 'status': {
                                                  'message': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                              'kind': 'message',
                                                              'messageId': '45240995-70ba-44ef-9b05-26bfa0c25299',
                                                              'metadata': {'author': 'PPTWriterSubAgent', 'show': True,
                                                                           'references': [
                                                                               'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                               'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                               'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                               'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                               'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                               'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                               'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                               'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                               'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                               'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                               'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                               'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                               'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                               'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                               'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                               'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                               'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                               'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                               'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                               'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                               'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                               'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                               'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                               'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                               'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                               'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                               'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                               'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                               'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                               'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                               'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                               'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                               'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                               'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                               'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                               'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                               'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                               'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                               'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                               'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                               'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                               'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                               'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                               'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                               'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                               'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                               'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                               'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                               'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                               'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                               'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                               'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                               'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                               'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                               'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                               'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                               'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                               'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                               'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                               'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                               'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                               'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                               'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                               'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                               'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                               'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                               'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                               'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                               'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                               'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                               'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                               'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                               'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                               'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                               'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                               'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                               'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                               "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                               'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                               'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                               'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                               'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                               'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                               'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                               'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                               'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                               'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                               'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                               'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                               'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                               'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                               'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                               'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                               'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                               'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                               'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                               'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                               'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                               'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                               'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                               'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                               'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                               'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                               'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                               'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                               'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                               'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                               'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                               'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                               'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                               'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                               'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                               'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                               'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                               'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                               'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                               'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                               'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                               'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                               'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                               'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                               'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                               'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                               'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                               'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                               'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                               'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                               'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                               'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                               'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                               'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                               'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                               'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                               'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                               'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                               'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                               'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                               'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                               'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                              'parts': [
                                                                  {'kind': 'text', 'text': '```xml\n<PRESENTATION>\n'}],
                                                              'role': 'agent',
                                                              'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                  'state': 'working', 'timestamp': '2025-07-25T08:30:11.191221+00:00'},
                                                     'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}
    first_page_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                               'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                          'final': False, 'kind': 'status-update', 'status': {
                                                       'message': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                                   'kind': 'message',
                                                                   'messageId': 'be6309ce-ae85-4c42-ab17-e6d80e420d97',
                                                                   'metadata': {'author': 'PPTWriterSubAgent',
                                                                                'show': True, 'references': [
                                                                           'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                           'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                           'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                           'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                           'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                           'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                           'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                           'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                           'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                           'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                           'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                           'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                           'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                           'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                           'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                           'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                           'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                           'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                           'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                           'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                           'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                           'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                           'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                           'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                           'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                           'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                           'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                           'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                           'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                           'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                           'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                           'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                           'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                           'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                           'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                           'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                           'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                           'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                           'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                           'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                           'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                           'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                           'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                           'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                           'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                           'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                           'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                           'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                           'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                           'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                           'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                           'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                           'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                           'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                           'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                           'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                           'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                           'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                           'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                           'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                           'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                           'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                           'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                           'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                           'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                           'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                           'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                           'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                           'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                           'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                           'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                           'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                           'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                           'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                           'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                           'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                           'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                           "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                           'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                           'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                           'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                           'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                           'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                           'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                           'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                           'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                           'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                           'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                           'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                           'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                           'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                           'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                           'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                           'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                           'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                           'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                           'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                           'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                           'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                           'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                           'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                           'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                           'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                           'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                           'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                           'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                           'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                           'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                           'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                           'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                           'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                           'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                           'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                           'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                           'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                           'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                           'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                           'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                           'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                           'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                           'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                           'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                           'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                           'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                           'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                           'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                           'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                           'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                           'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                           'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                           'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                           'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                           'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                           'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                           'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                           'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                           'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                           'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                           'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                                   'parts': [{'kind': 'text',
                                                                              'text': '```xml\n<!-- 第1页开始-->\n<SECTION layout="vertical" page_number=1>\n  <!-- 第1页正文内容-->\n  <H1>CAR-T细胞疗法在实体瘤治疗中的挑战与进展</H1>\n\n  <BULLETS>\n    <DIV><H3>CAR-T细胞疗法概述</H3><P>革命性免疫治疗方法，通过基因工程改造T细胞特异性识别肿瘤抗原</P></DIV>\n    <DIV><P>在血液系统恶性肿瘤中已取得显著成功，但在实体瘤治疗中仍面临诸多挑战</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV><H3>血液肿瘤成功案例</H3>\n      <P>• ALL完全缓解率70-90%</P>\n      <P>• DLBCL客观缓解率50-70%</P>\n      <P>• MM靶向BCMA显著疗效</P>\n    </DIV>\n    <DIV><H3>实体瘤主要挑战</H3>\n      <P>• 肿瘤异质性</P>\n      <P>• 物理屏障</P>\n      <P>• 免疫抑制微环境</P>\n      <P>• 靶向毒性</P>\n    </DIV>\n  </COLUMNS>\n\n  <!-- 背景图 -->\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="CAR-T细胞治疗概念图" background="true" />\n</SECTION>\n<!-- 第1页结束-->\n```'}],
                                                                   'role': 'agent',
                                                                   'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                       'state': 'working',
                                                       'timestamp': '2025-07-25T08:30:30.010109+00:00'},
                                                          'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}
    # 重复页面的更新
    first_seoncd_page_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                                      'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                                 'final': False, 'kind': 'status-update', 'status': {
                                                              'message': {
                                                                  'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                                  'kind': 'message',
                                                                  'messageId': 'be6309ce-ae85-4c42-ab17-e6d80e420d97',
                                                                  'metadata': {'author': 'PPTWriterSubAgent',
                                                                               'show': True, 'references': [
                                                                          'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                          'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                          'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                          'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                          'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                          'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                          'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                          'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                          'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                          'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                          'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                          'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                          'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                          'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                          'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                          'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                          'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                          'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                          'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                          'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                          'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                          'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                          'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                          'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                          'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                          'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                          'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                          'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                          'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                          'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                          'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                          'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                          'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                          'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                          'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                          'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                          'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                          'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                          'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                          'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                          'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                          'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                          'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                          'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                          'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                          'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                          'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                          'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                          'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                          'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                          'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                          'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                          'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                          'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                          'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                          'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                          'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                          'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                          'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                          'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                          'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                          'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                          'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                          'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                          'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                          'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                          'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                          'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                          'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                          'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                          'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                          'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                          'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                          'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                          'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                          'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                          'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                          "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                          'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                          'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                          'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                          'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                          'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                          'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                          'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                          'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                          'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                          'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                          'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                          'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                          'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                          'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                          'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                          'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                          'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                          'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                          'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                          'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                          'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                          'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                          'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                          'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                          'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                          'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                          'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                          'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                          'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                          'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                          'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                          'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                          'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                          'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                          'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                          'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                          'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                          'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                          'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                          'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                          'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                          'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                          'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                          'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                          'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                          'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                          'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                          'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                          'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                          'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                          'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                          'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                          'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                          'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                          'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                          'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                          'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                          'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                          'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                          'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                          'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                                  'parts': [{'kind': 'text',
                                                                             'text': '```xml\n<!-- 第1页开始-->\n<SECTION layout="vertical" page_number=1>\n  <!-- 第1页正文内容-->\n  <H1>CAR-T细胞疗法在实体瘤治疗中的挑战与进展（最新)</H1>\n\n  <BULLETS>\n    <DIV><H3>CAR-T细胞疗法概述</H3><P>革命性免疫治疗方法，通过基因工程改造T细胞特异性识别肿瘤抗原（最新)</P></DIV>\n    <DIV><P>在血液系统恶性肿瘤中已取得显著成功，但在实体瘤治疗中仍面临诸多挑战（最新)</P></DIV>\n  </BULLETS>\n\n  <COLUMNS>\n    <DIV><H3>血液肿瘤成功案例</H3>\n      <P>• ALL完全缓解率70-90%</P>\n      <P>• DLBCL客观缓解率50-70%</P>\n      <P>• MM靶向BCMA显著疗效</P>\n    </DIV>\n    <DIV><H3>实体瘤主要挑战</H3>\n      <P>• 肿瘤异质性</P>\n      <P>• 物理屏障</P>\n      <P>• 免疫抑制微环境</P>\n      <P>• 靶向毒性</P>\n    </DIV>\n  </COLUMNS>\n\n  <!-- 背景图 -->\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="CAR-T细胞治疗概念图" background="true" />\n</SECTION>\n<!-- 第1页结束-->\n```'}],
                                                                  'role': 'agent',
                                                                  'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                              'state': 'working',
                                                              'timestamp': '2025-07-25T08:30:30.010109+00:00'},
                                                                 'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}
    second_page_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                                'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                           'final': False, 'kind': 'status-update', 'status': {
                                                        'message': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                                    'kind': 'message',
                                                                    'messageId': '13ba8de0-da27-4934-a844-fccde44f30f9',
                                                                    'metadata': {'author': 'PPTWriterSubAgent',
                                                                                 'show': True, 'references': [
                                                                            'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                            'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                            'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                            'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                            'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                            'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                            'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                            'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                            'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                            'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                            'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                            'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                            'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                            'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                            'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                            'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                            'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                            'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                            'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                            'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                            'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                            'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                            'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                            'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                            'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                            'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                            'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                            'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                            'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                            'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                            'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                            'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                            'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                            'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                            'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                            'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                            'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                            'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                            'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                            'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                            'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                            'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                            'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                            'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                            'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                            'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                            'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                            'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                            'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                            'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                            'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                            'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                            'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                            'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                            'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                            'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                            'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                            'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                            'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                            'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                            'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                            'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                            'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                            'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                            'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                            'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                            'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                            'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                            'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                            'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                            'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                            'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                            'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                            'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                            'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                            'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                            'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                            "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                            'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                            'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                            'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                            'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                            'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                            'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                            'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                            'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                            'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                            'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                            'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                            'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                            'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                            'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                            'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                            'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                            'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                            'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                            'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                            'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                            'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                            'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                            'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                            'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                            'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                            'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                            'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                            'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                            'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                            'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                            'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                            'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                            'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                            'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                            'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                            'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                            'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                            'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                            'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                            'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                            'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                            'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                            'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                            'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                            'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                            'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                            'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                            'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                            'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                            'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                            'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                            'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                            'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                            'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                            'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                            'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                            'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                            'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                            'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                            'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                            'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                                    'parts': [{'kind': 'text',
                                                                               'text': '```xml\n<!-- 第2页开始-->\n<SECTION layout="vertical" page_number=2>\n  <!-- 第2页正文内容-->\n  <H1>CAR-T细胞的基本原理和发展历程</H1>\n\n  <BULLETS>\n    <DIV><H3>CAR-T细胞核心结构</H3>\n      <P>• 胞外抗原识别区(scFv)</P>\n      <P>• 跨膜区</P>\n      <P>• 胞内信号转导区</P>\n    </DIV>\n  </BULLETS>\n\n  <STAIRCASE>\n    <DIV><H3>第一代CAR</H3><P>仅含CD3ζ信号域，激活能力有限</P></DIV>\n    <DIV><H3>第二代CAR</H3><P>加入共刺激分子(CD28/4-1BB)，增强活化和持久性</P></DIV>\n    <DIV><H3>第三代CAR</H3><P>包含两个共刺激分子，优化信号传导</P></DIV>\n    <DIV><H3>第四代CAR</H3><P>"装甲CAR"，整合细胞因子分泌功能</P></DIV>\n  </STAIRCASE>\n\n  <TIMELINE>\n    <DIV><H3>1989年</H3><P>Eshhar首次提出嵌合受体概念</P></DIV>\n    <DIV><H3>2017年</H3><P>FDA批准首个CAR-T产品(Kymriah)</P></DIV>\n    <DIV><H3>2024年</H3><P>全球多款CAR-T产品获批，中国进入快速发展阶段</P></DIV>\n  </TIMELINE>\n\n  <!-- 背景图 -->\n  <IMG src="https://img.infox-med.com/images/38882528/439ffca0598067e0921dafadf6d948c2f5c2d40736fd7659cb9ae7a5894554a7.jpg" alt="CAR-T细胞结构示意图" background="false" />\n</SECTION>\n<!-- 第2页结束-->\n```'}],
                                                                    'role': 'agent',
                                                                    'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                        'state': 'working',
                                                        'timestamp': '2025-07-25T08:30:55.060825+00:00'},
                                                           'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}
    end_xml = {'type': 'data', 'text': {'id': '983c6cd20b9c4a03b3dbcdee5e91b56d', 'jsonrpc': '2.0',
                                        'result': {'contextId': '65700110-13a1-4643-8528-282d47a8b269', 'final': False,
                                                   'kind': 'status-update', 'status': {
                                                'message': {'contextId': '65700110-13a1-4643-8528-282d47a8b269',
                                                            'kind': 'message',
                                                            'messageId': 'b4984098-b8de-46c1-9fe4-e585ef95943b',
                                                            'metadata': {'author': 'PPTWriterSubAgent', 'show': True,
                                                                         'references': [
                                                                             'Next generations of CAR-T cells - new therapeutic opportunities in hematology? -- PMID:36389658',
                                                                             'Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses -- PMID:34341066',
                                                                             'Optimizing CAR-T cell function in solid tumor microenvironment: insights from culture media additives -- PMID:39798497',
                                                                             'Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering -- PMID:35005887',
                                                                             'Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology -- PMID:38070114',
                                                                             'Engineering the next generation of CAR-NK immunotherapies -- PMID:34453686',
                                                                             'CAR-T cells: the Chinese experience -- PMID:32605454',
                                                                             'Application and prospects of genetic engineering in CAR-NK cell therapy -- PMID:40486523',
                                                                             'Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing -- PMID:35303871',
                                                                             'Current state and next-generation CAR-T cells in multiple myeloma -- PMID:35131139',
                                                                             'Challenges and optimal strategies of CAR T therapy for hematological malignancies -- PMID:36848181',
                                                                             'Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors -- PMID:36429054',
                                                                             'Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting -- PMID:35686214',
                                                                             'Automated generation of gene-edited CAR T cells at clinical scale -- PMID:33575430',
                                                                             'Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming -- PMID:40328248',
                                                                             'Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy -- PMID:33883875',
                                                                             'Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy -- PMID:39455854',
                                                                             'CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells -- PMID:40022447',
                                                                             'Engineering strategies to safely drive CAR T-cells into the future -- PMID:38962002',
                                                                             'CAR-T cell combination therapies in hematologic malignancies -- PMID:39026380',
                                                                             'CAR-T Therapies in Solid Tumors: Opportunities and Challenges -- PMID:36853475',
                                                                             'Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development -- PMID:37803832',
                                                                             'Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells -- PMID:33417830',
                                                                             'Ferroelectric α-In2Se3 Semi-floating Gate Transistors for Multilevel Memory and Optoelectronic Logic Gate -- PMID:40267295',
                                                                             'Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy -- PMID:36167591',
                                                                             'J-MISFET Hybrid Dual-Gate Switching Device for Multifunctional Optoelectronic Logic Gate Applications -- PMID:38629449',
                                                                             'Fully human antibody VH domains to generate mono and bispecific CAR to target solid tumors -- PMID:33795386',
                                                                             'Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy -- PMID:39187850',
                                                                             'Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies -- PMID:37853078',
                                                                             'Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma -- PMID:40528279',
                                                                             'IL-18 revives dysfunctional CAR-T cells -- PMID:40628538',
                                                                             'Optimization of lymphapheresis for manufacturing autologous CAR-T cells -- PMID:34275066',
                                                                             'Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies -- PMID:39098176',
                                                                             'The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade -- PMID:32246174',
                                                                             'Artificial intelligence and machine learning applications in biopharmaceutical manufacturing -- PMID:36117026',
                                                                             'TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy -- PMID:34988114',
                                                                             'Implantable CAR T cell factories enhance solid tumor treatment -- PMID:38640784',
                                                                             'All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy -- PMID:32109718',
                                                                             'A next generation inducible armored CAR to overcome the immunosuppressive tumor microenvironment and enhances cytotoxicity of CAR-T and TILs. -- PMID:-38494',
                                                                             'Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia -- PMID:39095503',
                                                                             'Optimizing CAR-T cell Culture: Differential effects of IL-2, IL-12, and IL-21 on CAR-T cells -- PMID:39299100',
                                                                             'Three-input logic gate based on DNA strand displacement reaction -- PMID:37709846',
                                                                             'Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy -- PMID:39905727',
                                                                             'Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy -- PMID:33711191',
                                                                             'IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation -- PMID:34298748',
                                                                             'Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma -- PMID:38882528',
                                                                             'Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers -- PMID:38639669',
                                                                             'Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells -- PMID:39702858',
                                                                             'Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control -- PMID:38394207',
                                                                             'Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells -- PMID:40437756',
                                                                             'Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma -- PMID:33543339',
                                                                             'Effects of CAR structure and culture conditions on memory CAR-T cells -- PMID:33755968',
                                                                             'STING agonist promotes CAR T cell trafficking and persistence in breast cancer -- PMID:33382402',
                                                                             'Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment -- PMID:33532902',
                                                                             'Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy -- PMID:36168626',
                                                                             'Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment -- PMID:33785843',
                                                                             'In vivo CAR engineering for immunotherapy -- PMID:40379910',
                                                                             'Multiple-input hybrid plasmonic OR logic gate with a nanostructure -- PMID:36821259',
                                                                             'Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells -- PMID:32902645',
                                                                             'Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment -- PMID:38762281',
                                                                             'Human chimeric antigen receptor macrophages for cancer immunotherapy -- PMID:32361713',
                                                                             'Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects -- PMID:40483473',
                                                                             'Dual targeting ovarian cancer by Muc16 CAR-T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37214945',
                                                                             'Oncolytic virus and CAR-T cell therapy in solid tumors -- PMID:39539554',
                                                                             'Scalable Manufacturing of CAR T cells for Cancer Immunotherapy -- PMID:34568831',
                                                                             'Ethical and Bias Considerations in Artificial Intelligence (AI)/Machine Learning -- PMID:39694331',
                                                                             'Review of Machine Learning and Artificial Intelligence (ML/AI) for the Pediatric Neurologist -- PMID:36773406',
                                                                             'Modulating tumor physical microenvironment for fueling CAR-T cell therapy -- PMID:35439570',
                                                                             'Phase I CAR-T Clinical Trials Review -- PMID:36456127',
                                                                             'Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors -- PMID:37976958',
                                                                             'Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy -- PMID:33643299',
                                                                             'CAR-T therapy in solid tumors -- PMID:40233718',
                                                                             'Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy -- PMID:33933160',
                                                                             'Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response -- PMID:35592358',
                                                                             'LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment -- PMID:37408308',
                                                                             'Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials -- PMID:35559800',
                                                                             'Combining chemotherapy with CAR-T cell therapy in treating solid tumors -- PMID:36949946',
                                                                             "Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma -- PMID:40210237",
                                                                             'Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer -- PMID:37028461',
                                                                             'Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors -- PMID:34721401',
                                                                             'Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy -- PMID:33890832',
                                                                             'CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy -- PMID:35352167',
                                                                             'Vascularized tumor-on-a-chip to investigate immunosuppression of CAR-T cells -- PMID:40289711',
                                                                             'Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment -- PMID:36707873',
                                                                             'Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells -- PMID:35573047',
                                                                             'Analysis of causes for poor persistence of CAR-T cell therapy in vivo -- PMID:36761742',
                                                                             'Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology -- PMID:38449862',
                                                                             'Probiotic-guided CAR-T cells for solid tumor targeting -- PMID:37824640',
                                                                             'CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors -- PMID:39933839',
                                                                             'Combinatorial CAR design improves target restriction -- PMID:33234592',
                                                                             'Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies -- PMID:40090318',
                                                                             'The Mechanisms and Countermeasures for CAR-T cell Expansion and Persistence Deficiency -- PMID:40320041',
                                                                             'Dual-target CAR-T cell therapy: a new strategy to improve the therapeutic effect of hematological malignancies -- PMID:40609918',
                                                                             'CAR T-cell and oncolytic virus dynamics and determinants of combination therapy success for glioblastoma -- PMID:39896563',
                                                                             'DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response -- PMID:40578903',
                                                                             'A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers -- PMID:38928301',
                                                                             'Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals -- PMID:33804441',
                                                                             'Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors -- PMID:39835140',
                                                                             'CAR T cell therapy in solid tumors: A review of current clinical trials -- PMID:35844304',
                                                                             'Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy -- PMID:38225288',
                                                                             'CAR-T cells and BiTEs in solid tumors: challenges and perspectives -- PMID:33874996',
                                                                             'Presetting CAR-T cells during ex vivo bio-manufacturing -- PMID:39988874',
                                                                             'Targeting B7-H3 in solid tumors: Development and evaluation of novel CAR-T Cell therapy -- PMID:40121824',
                                                                             'CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual targeting antibody overcome antigen heterogeneity in AML -- PMID:39571145',
                                                                             'Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy -- PMID:36681183',
                                                                             'A review on patient-specific facial and cranial implant design using Artificial Intelligence (AI) techniques -- PMID:34404280',
                                                                             'HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity -- PMID:38097342',
                                                                             'Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield -- PMID:32731404',
                                                                             'Next-Generation CAR T-cell Therapies -- PMID:35417527',
                                                                             'Recommendations for the use of pediatric data in artificial intelligence and machine learning ACCEPT-AI -- PMID:37673925',
                                                                             'Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors -- PMID:40599347',
                                                                             'Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors -- PMID:39456909',
                                                                             'Improving CAR T-Cell Persistence -- PMID:34639168',
                                                                             'CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors -- PMID:39134804',
                                                                             'Dual CAR-T cells targeting CD19 and CD37 are effective in target antigen loss B cell tumor models -- PMID:37828726',
                                                                             'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice -- PMID:35672571',
                                                                             'Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy -- PMID:40289115',
                                                                             'CAR-armored-cell therapy in solid tumor treatment -- PMID:39609705',
                                                                             'Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1 -- PMID:37635172',
                                                                             'CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells -- PMID:37645216',
                                                                             'Strategies to enhance CAR-T persistence -- PMID:36419115',
                                                                             'Therapeutic advantage of combinatorial CAR T cell and chemo-therapies -- PMID:39375047',
                                                                             'Recent Advances in CAR-Based Solid Tumor Immunotherapy -- PMID:37371075',
                                                                             'Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating -- PMID:36961206',
                                                                             'The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice -- PMID:33738341',
                                                                             'GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency -- PMID:39370422',
                                                                             'Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells -- PMID:39294295',
                                                                             'Impact of Manufacturing Procedures on CAR T Cell Functionality -- PMID:35493513',
                                                                             'Engineering enhanced CAR T-cells for improved cancer therapy -- PMID:34485921',
                                                                             'Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy -- PMID:37251405',
                                                                             'The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy -- PMID:39111352',
                                                                             'Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors -- PMID:35202772',
                                                                             'Tumor-Targeted Nonablative Radiation Promotes Solid Tumor CAR T-cell Therapy Efficacy -- PMID:37540803',
                                                                             'Next-Generation CAR-T and TCR-T Cell Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends -- PMID:40563595',
                                                                             'Steering CAR T cell epigenetic programs by tweaking manufacturing protocol -- PMID:37343521',
                                                                             'TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma -- PMID:34249750',
                                                                             'Engineering CAR-T Therapeutics for Enhanced Solid Tumor Targeting -- PMID:39745117',
                                                                             'Regulatory Approval of CAR-T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan -- PMID:40084978',
                                                                             'TALEN-edited Allogeneic Inducible Dual CAR T-cells Enable Effective Targeting of Solid Tumors while Mitigating Off-Tumor Toxicity -- PMID:39169622']},
                                                            'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}],
                                                            'role': 'agent',
                                                            'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'},
                                                'state': 'working', 'timestamp': '2025-07-25T08:32:11.642206+00:00'},
                                                   'taskId': '034617b6-4449-446c-ba9e-0ee65600349a'}}}
    Stream = [first_xml, first_page_xml, first_seoncd_page_xml, second_page_xml, end_xml]
    # 用于存储每个页码对应的XML内容，键为页码，值为XML字符串
    page_xml_map = {}

    # 用于存储 <PRESENTATION> 和 </PRESENTATION> 这类非页码部分的XML
    overall_start_xml = ""
    overall_end_xml = ""

    # 存储最新的references
    latest_references = []

    # 正则表达式用于从 <SECTION> 标签中提取 page_number 属性
    # pattern = re.compile(r'<SECTION[^>]*page_number=(\d+)[^>]*>')
    # 改进的正则表达式，以匹配 page_number="1" 或 page_number=1 等多种情况
    # 同时确保只匹配 <SECTION ...> 标签中的 page_number
    # [^>]* 匹配除了 > 之外的任何字符，0次或多次
    # page_number=(\d+|"\d+") 匹配 page_number=数字 或 page_number="数字"
    page_number_pattern = re.compile(r'<SECTION[^>]+page_number\s*=\s*["\']?(\d+)["\']?[^>]*>')

    for one in Stream:
        # 提取 XML 文本内容
        content_parts = one["text"]["result"]["status"]["message"]["parts"]
        text_content = content_parts[0]["text"]

        # --- 移除 Markdown XML block 分隔符 ---
        start_delimiter = "```xml\n"
        end_delimiter = "```"
        if text_content.startswith(start_delimiter):
            text_content = text_content[len(start_delimiter):]
        if text_content.endswith(end_delimiter):
            text_content = text_content[:-len(end_delimiter)]

        # 移除 XML 注释行，例如 <!-- 第1页开始-->
        text_content = re.sub(r'<!--.*?-->\n?', '', text_content)

        # 更新 references，始终保留最新的
        latest_references = one["text"]["result"]["status"]["message"]["metadata"]["references"]

        # 尝试匹配 page_number
        match = page_number_pattern.search(text_content)

        if match:
            # 如果找到 page_number，则将其作为键存储，值是整个 SECTION 块的 XML
            page_number = int(match.group(1))
            page_xml_map[page_number] = text_content.strip()  # .strip() 移除多余的空白行
        elif text_content.strip() == '<PRESENTATION>':
            overall_start_xml = text_content.strip()
        elif text_content.strip() == '</PRESENTATION>':
            overall_end_xml = text_content.strip()

    # 按照页码顺序拼接最终的 XML 内容
    final_xml_parts = []

    if overall_start_xml:
        final_xml_parts.append(overall_start_xml)

    # 获取所有页码，并进行排序
    sorted_page_numbers = sorted(page_xml_map.keys())

    for page_num in sorted_page_numbers:
        final_xml_parts.append(page_xml_map[page_num])

    if overall_end_xml:
        final_xml_parts.append(overall_end_xml)

    PPT_content = "\n".join(final_xml_parts)  # 使用换行符连接各部分，保持可读性

    return PPT_content, latest_references
def generate_ppt_xml_third():
    # page_number相同的会被替换
    Stream = [{'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '791921e1-8f4c-4e8f-8a64-8767be4112c0', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '```xml\n<PRESENTATION>\n'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:07.212097+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '4fcc7415-b20d-4a15-bbfd-f889bc34a171', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '```xml\n<!-- 第1页开始-->\n<SECTION layout="vertical" page_number=1>\n  <H1>Atherosclerosis as an Inflammatory Disease</H1>\n\n  <BULLETS>\n    <DIV><H3>Traditional View vs. Modern Understanding</H3><P>Atherosclerosis was long seen as a lipid disorder—but now recognized as a chronic inflammatory condition involving immune cells and vascular dysfunction.</P></DIV>\n    <DIV><P>Immune mechanisms drive plaque initiation, progression, and destabilization—making inflammation a central therapeutic target.</P></DIV>\n    <DIV><P>Key players: macrophages, T cells, B cells, dendritic cells, and cytokines like IL-1β, TNF-α, and IL-6.</P></DIV>\n  </BULLETS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background1.jpg" alt="背景图：动脉炎症示意图，突出免疫细胞浸润与斑块形成" background="true" />\n</SECTION>\n<!-- 第1页结束-->\n```'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:11.069585+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'a11c370d-25ff-412e-b638-965d9623a8e9', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第2页开始-->\n<SECTION layout="vertical" page_number=2>\n  <H1>Immune Mechanisms in Atherosclerosis: Innate and Adaptive Responses</H1>\n\n  <BULLETS>\n    <DIV><H3>Innate Immunity: Macrophages & Dendritic Cells</H3><P>Macrophages infiltrate early lesions, become foam cells by engulfing oxidized LDL, and drive inflammation via IL-1β, TNF-α.</P></DIV>\n    <DIV><P>Dendritic cells act as bridges between innate and adaptive immunity—presenting antigens to T cells and shaping plaque-specific immune responses.</P></DIV>\n    <DIV><H3>Adaptive Immunity: T and B Cell Roles</H3><P>T cells (Th1, Th17) amplify inflammation; regulatory T cells (Tregs) suppress it—balancing plaque progression vs. stability.</P></DIV>\n    <DIV><P>B cells produce antibodies against oxidized LDL; some IgG subclasses may promote inflammation, while natural IgM protects by clearing debris.</P></DIV>\n  </BULLETS>\n\n  <IMG src="https://upload.wikimedia.org/wikipedia/commons/thumb/3/35/Immune-cells-atherosclerosis.svg/1200px-Immune-cells-atherosclerosis.svg.png" alt="免疫细胞在动脉粥样硬化斑块中的相互作用示意图：巨噬细胞、T细胞、B细胞、树突状细胞等" background="false" />\n</SECTION>\n<!-- 第2页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:17.009482+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'e0ca736a-4b10-405d-a478-91060a762e01', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第2页开始-->\n<SECTION layout="columns" page_number=2>\n  <H1>Immune Mechanisms in Atherosclerosis: Innate vs. Adaptive Responses</H1>\n\n  <COLUMNS>\n    <DIV>\n      <H3>Innate Immune System</H3>\n      <P>Macrophages and dendritic cells are first responders to endothelial injury, initiating inflammation through pattern recognition receptors (e.g., TLRs).</P>\n      <P>They phagocytose modified LDL, transforming into foam cells—the hallmark of early atherosclerotic lesions.</P>\n      <P>Activation leads to cytokine release (IL-1β, TNF-α), promoting leukocyte recruitment and plaque progression.</P>\n    </DIV>\n    \n    <DIV>\n      <H3>Adaptive Immune System</H3>\n      <P>T cells (Th1, Th17) drive pro-inflammatory responses via IFN-γ and IL-17, enhancing macrophage activation and vascular dysfunction.</P>\n      <P>B cells produce antibodies against oxidized LDL; some IgG subclasses may promote inflammation, while natural IgM protects by clearing debris.</P>\n      <P>Immune cell crosstalk between T and B cells determines whether plaques stabilize or destabilize.</P>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://img.infox-med.com/images/36912045/113a43cbe73938b9eff82cee7a462ddbcb628cad89e52ba06fb888f191ae47ef.jpg" alt="Ivonescimab结合T细胞的示意图，展示免疫调节机制在动脉粥样硬化中的作用" background="false" />\n</SECTION>\n<!-- 第2页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:24.427647+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '633fdf80-a820-4265-a0d9-e793c74d5134', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第3页开始-->\n<SECTION layout="columns" page_number=3>\n  <H1>Macrophage Polarization and Foam Cell Formation in Atherosclerosis</H1>\n\n  <COLUMNS>\n    <DIV>\n      <H3>M1 Macrophages: Pro-Inflammatory Drivers</H3>\n      <P>Activated by IFN-γ and TLR ligands, M1 macrophages secrete IL-1β, TNF-α, and reactive oxygen species.</P>\n      <P>They promote plaque instability by degrading extracellular matrix and recruiting more immune cells.</P>\n      <P>Key markers: iNOS, CD86, IL-12.</P>\n    </DIV>\n    \n    <DIV>\n      <H3>M2 Macrophages: Reparative and Anti-Inflammatory</H3>\n      <P>Induced by IL-4 and IL-13, M2 macrophages produce IL-10 and TGF-β to resolve inflammation.</P>\n      <P>Support fibrosis and tissue repair but may contribute to plaque cap thickening if overactive.</P>\n      <P>Key markers: CD206, Arg1, IL-10.</P>\n    </DIV>\n  </COLUMNS>\n\n  <TABLE>\n    <TR><TH>Macrophage Subtype</TH><TH>Function</TH><TH>Marker Cytokines</TH><TH>Role in Atherosclerosis</TH></TR>\n    <TR><TD>M1</TD><TD>Pro-inflammatory</TD><TD>IL-1β, TNF-α</TD><TD>Plaque instability</TD></TR>\n    <TR><TD>M2</TD><TD>Anti-inflammatory</TD><TD>IL-10, TGF-β</TD><TD>Resolution, fibrosis</TD></TR>\n    <TR><TD>Foam cell</TD><TD>Lipid-laden, inflammatory</TD><TD>-</TD><TD>Core of atheroma, necrosis</TD></TR>\n  </TABLE>\n\n  <IMG src="https://upload.wikimedia.org/wikipedia/commons/thumb/3/35/Immune-cells-atherosclerosis.svg/1200px-Immune-cells-atherosclerosis.svg.png" alt="免疫细胞在动脉粥样硬化斑块中的相互作用示意图，包括M1/M2巨噬细胞和泡沫细胞" background="false" />\n</SECTION>\n<!-- 第3页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:33.424924+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'cd989f16-ec21-41b3-bcf4-10dc9cecc03b', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第3页开始-->\n<SECTION layout="staircase" page_number=3>\n  <H1>Macrophage Polarization and Foam Cell Formation in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Early Inflammation</H3><P>Monocytes recruited to injured endothelium differentiate into macrophages, initiating plaque formation.</P></DIV>\n    <DIV><H3>Pro-Inflammatory Phase (M1)</H3><P>M1 macrophages secrete IL-1β, TNF-α, and ROS, driving foam cell formation and plaque progression.</P></DIV>\n    <DIV><H3>Reparative Phase (M2)</H3><P>M2 macrophages produce IL-10 and TGF-β, promoting fibrosis and lesion stabilization—key for resolving inflammation.</P></DIV>\n    <DIV><H3>Plaque Destabilization</H3><P>Excessive lipid uptake leads to foam cell death, necrotic core expansion, and vulnerability to rupture.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://img.infox-med.com/images/36912045/113a43cbe73938b9eff82cee7a462ddbcb628cad89e52ba06fb888f191ae47ef.jpg" alt="Ivonescimab结合T细胞的示意图，展示免疫调节机制在动脉粥样硬化中的作用" background="false" />\n</SECTION>\n<!-- 第3页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:41.082584+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'bc333d71-b5e1-43b3-b36e-04609e58b64d', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第3页开始-->\n<SECTION layout="staircase" page_number=3>\n  <H1>Macrophage Polarization and Foam Cell Formation in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Early Inflammation</H3><P>Monocytes recruited to injured endothelium differentiate into macrophages, initiating plaque formation.</P></DIV>\n    <DIV><H3>Pro-inflammatory M1 Macrophages</H3><P>Secrete IL-1β, TNF-α, and reactive oxygen species—promoting lesion progression and matrix degradation.</P></DIV>\n    <DIV><H3>Foam Cell Formation</H3><P>Uptake of oxidized LDL via scavenger receptors leads to lipid accumulation—hallmark of early atheroma.</P></DIV>\n    <DIV><H3>Reparative M2 Macrophages</H3><P>Produce IL-10 and TGF-β—support tissue repair, fibrosis, and plaque stabilization.</P></DIV>\n    <DIV><H3>Plaque Destabilization</H3><P>Imbalance favoring M1 over M2 drives necrotic core expansion, thinning of fibrous cap, and rupture risk.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background2.jpg" alt="背景图：动脉粥样硬化中巨噬细胞极化与泡沫细胞形成的示意图，突出M1和M2巨噬细胞的作用差异" background="true" />\n</SECTION>\n<!-- 第3页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:49.675376+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '52069838-9de9-4a26-8b80-85844f0611c4', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第4页开始-->\n<SECTION layout="staircase" page_number=4>\n  <H1>Inflammatory Cytokines and Chemokines in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Key Pro-Inflammatory Cytokines</H3><P>IL-1β, TNF-α, and IL-6 are central mediators that amplify endothelial activation, leukocyte recruitment, and plaque progression.</P></DIV>\n    <DIV><H3>Role of IL-1β</H3><P>Drives monocyte recruitment via upregulation of adhesion molecules and chemokines like MCP-1; promotes foam cell formation and smooth muscle cell dysfunction.</P></DIV>\n    <DIV><H3>Chemokine-Mediated Recruitment</H3><P>CCL2/MCP-1 is critical for monocyte trafficking into the arterial intima—targeting this pathway reduces lesion size in animal models.</P></DIV>\n    <DIV><H3>Feedback Amplification Loop</H3><P>Cytokines activate vascular cells and immune effectors, which in turn produce more cytokines—creating a self-sustaining inflammatory cycle within plaques.</P></DIV>\n    <DIV><H3>Therapeutic Relevance</H3><P>Blocking these signals (e.g., with canakinumab targeting IL-1β) has shown clinical benefit in reducing cardiovascular events independent of lipid lowering.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background3.jpg" alt="背景图：动脉粥样硬化中炎症因子（如IL-1β、TNF-α）与趋化因子（如CCL2）相互作用的示意图，突出其在免疫细胞募集和斑块进展中的作用" background="true" />\n</SECTION>\n<!-- 第4页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:05:57.499232+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'd1c6ec80-5d89-462a-8d35-51275d943f42', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第5页开始-->\n<SECTION layout="staircase" page_number=5>\n  <H1>T Cell Subsets and Their Impact in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Th1 Cells: Pro-Inflammatory Drivers</H3><P>Secrete IFN-γ, which activates macrophages, enhances foam cell formation, and promotes endothelial dysfunction—driving plaque progression.</P></DIV>\n    <DIV><H3>Th17 Cells: Plaque Destabilizers</H3><P>Produce IL-17, recruiting neutrophils and amplifying local inflammation; associated with thin fibrous caps and rupture-prone plaques.</P></DIV>\n    <DIV><H3>Tregs (Regulatory T Cells): Protective Modulators</H3><P>Suppress effector T cells via IL-10 and TGF-β, maintain immune tolerance, and promote plaque stability—key targets for immunotherapy.</P></DIV>\n    <DIV><H3>Imbalance Determines Outcome</H3><P>Shift from Treg dominance to Th1/Th17 excess correlates with advanced disease and increased cardiovascular events—highlighting the need for immune balance.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background4.jpg" alt="背景图：动脉粥样硬化中T细胞亚群（Th1、Th17、Treg）相互作用示意图，突出其对斑块稳定性和炎症状态的调控作用" background="true" />\n</SECTION>\n<!-- 第5页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:03.338175+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '797cf608-34ee-4d08-b097-aa2039a0eb72', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第6页开始-->\n<SECTION layout="staircase" page_number=6>\n  <H1>B Cell-Mediated Antibody Responses in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Natural IgM Antibodies: Protective Role</H3><P>Produced by B-1 cells, natural IgM targets oxidized LDL and apoptotic cells—promoting clearance and reducing inflammation.</P></DIV>\n    <DIV><H3>IgG Subclasses: Dual Effects</H3><P>Certain IgG subclasses (e.g., IgG1) can enhance foam cell formation and complement activation—driving plaque progression.</P></DIV>\n    <DIV><H3>Antigen Presentation by B Cells</H3><P>B cells act as antigen-presenting cells for T cells, influencing the balance between pro-inflammatory and regulatory immune responses within plaques.</P></DIV>\n    <DIV><H3>Autoantibody Formation</H3><P>Loss of tolerance to self-antigens like oxidized LDL leads to pathogenic autoantibodies that may promote vascular injury and chronic inflammation.</P></DIV>\n    <DIV><H3>Therapeutic Implications</H3><P>Modulating B cell activity—either by enhancing protective IgM or suppressing harmful IgG—is a promising immunotherapeutic strategy in atherosclerosis.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background5.jpg" alt="背景图：动脉粥样硬化中B细胞介导的抗体反应示意图，突出自然IgM与致病性IgG的作用差异" background="true" />\n</SECTION>\n<!-- 第6页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:10.336385+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '06a225c0-35f0-4514-8666-37e92364647e', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第7页开始-->\n<SECTION layout="staircase" page_number=7>\n  <H1>Neutrophil Extracellular Traps (NETs) in Plaque Instability</H1>\n\n  <STAIRCASE>\n    <DIV><H3>What Are NETs?</H3><P>Neutrophil Extracellular Traps (NETs) are web-like structures composed of DNA, histones, and antimicrobial proteins released by activated neutrophils during inflammation.</P></DIV>\n    <DIV><H3>Role in Atherosclerosis</H3><P>NETs promote endothelial dysfunction, enhance pro-inflammatory cytokine production, and directly contribute to plaque rupture by degrading the fibrous cap and activating thrombotic pathways.</P></DIV>\n    <DIV><H3>NETs and Thrombosis</H3><P>They provide a scaffold for platelet adhesion and activation, facilitating thrombus formation upon plaque rupture—linking inflammation to acute cardiovascular events.</P></DIV>\n    <DIV><H3>Therapeutic Target Potential</H3><P>Targeting NET formation (e.g., via PAD4 inhibition) or degradation (e.g., DNase I) is emerging as a novel strategy to reduce plaque instability and prevent acute coronary syndromes.</P></DIV>\n    <DIV><H3>Current Evidence</H3><P>Human studies show elevated NET markers in patients with unstable angina and acute myocardial infarction; animal models confirm that NET inhibition reduces lesion severity and thrombogenicity.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background6.jpg" alt="背景图：动脉粥样硬化中中性粒细胞胞外诱捕网（NETs）在斑块不稳定和血栓形成中的作用示意图，突出其与内皮损伤、炎症放大和血栓风险的关系" background="true" />\n</SECTION>\n<!-- 第7页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:19.482182+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'f3185202-38a8-4498-8c73-16cb1113def5', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第8页开始-->\n<SECTION layout="staircase" page_number=8>\n  <H1>Cardiovascular Immunotherapy Potential: Targeting Inflammatory Pathways</H1>\n\n  <STAIRCASE>\n    <DIV><H3>IL-1β as a Central Therapeutic Target</H3><P>Interleukin-1β (IL-1β) is a master regulator of inflammation in atherosclerosis, driving monocyte recruitment, foam cell formation, and endothelial dysfunction.</P></DIV>\n    <DIV><H3>CANTOS Trial Evidence</H3><P>The CANTOS trial demonstrated that canakinumab—a monoclonal antibody targeting IL-1β—reduced major adverse cardiovascular events (MACE) by 15% in high-risk patients, independent of lipid-lowering effects.</P></DIV>\n    <DIV><H3>TNF-α Inhibition: Promise and Caution</H3><P>Anti-TNF-α therapies show potential but carry risks of infection and paradoxical cardiovascular events; ongoing trials are evaluating safety in cardiovascular populations.</P></DIV>\n    <DIV><H3>Other Targets Under Investigation</H3><P>Emerging targets include IL-6, NLRP3 inflammasome, and chemokine receptors like CCR2—each offering new avenues for precision immunomodulation.</P></DIV>\n    <DIV><H3>Therapeutic Implications</H3><P>These findings validate the concept that targeting specific inflammatory pathways can reduce cardiovascular risk beyond traditional lipid management—ushering in a new era of immunomodulatory therapy.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background7.jpg" alt="背景图：动脉粥样硬化中靶向炎症通路（如IL-1β、TNF-α）的免疫治疗示意图，突出其在减少心血管事件中的作用" background="true" />\n</SECTION>\n<!-- 第8页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:27.755824+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '3b4956fa-c61b-47f5-9758-c88a2dcdea10', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第9页开始-->\n<SECTION layout="staircase" page_number=9>\n  <H1>Immune Checkpoint Inhibitors in Atherosclerosis: Double-Edged Sword</H1>\n\n  <STAIRCASE>\n    <DIV><H3>What Are Immune Checkpoints?</H3><P>Immune checkpoints (e.g., PD-1/PD-L1, CTLA-4) are regulatory pathways that maintain immune tolerance and prevent excessive activation—critical for preventing autoimmunity.</P></DIV>\n    <DIV><H3>Role in Atherosclerosis</H3><P>In atherosclerotic plaques, these checkpoints are often upregulated as a compensatory mechanism to limit T cell-driven inflammation—yet their activity may also suppress protective immune responses.</P></DIV>\n    <DIV><H3>Therapeutic Paradox</H3><P>Blockade of immune checkpoints (as used in cancer immunotherapy) can unleash pathogenic T cells, potentially accelerating plaque progression or triggering acute events like myocardial infarction.</P></DIV>\n    <DIV><H3>Evidence from Oncology</H3><P>Clinical cases show increased cardiovascular events in patients receiving checkpoint inhibitors—highlighting the risk of disrupting vascular immune homeostasis.</P></DIV>\n    <DIV><H3>Future Considerations</H3><P>Understanding the balance between immune activation and regulation is key—targeted modulation rather than broad inhibition may be safer and more effective in cardiovascular disease settings.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background8.jpg" alt="背景图：动脉粥样硬化中免疫检查点（如PD-1/PD-L1）在T细胞调控中的双重作用示意图，突出其对炎症平衡的影响" background="true" />\n</SECTION>\n<!-- 第9页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:35.534481+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'cb3a6a16-0f11-4034-be27-3605a715b37a', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第10页开始-->\n<SECTION layout="staircase" page_number=10>\n  <H1>Vaccination Strategies Against Atherosclerosis Antigens</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Concept of Atherosclerosis Vaccines</H3><P>Experimental vaccines aim to induce protective immune responses against key antigens such as oxidized LDL, ApoB-100 peptides, and heat shock proteins—targeting the autoimmune component of atherosclerosis.</P></DIV>\n    <DIV><H3>Inducing Immune Tolerance</H3><P>By promoting regulatory T cell (Treg) activation or blocking pathogenic T cell responses, vaccines may restore immune homeostasis in the vessel wall without causing systemic immunosuppression.</P></DIV>\n    <DIV><H3>Preclinical Success</H3><P>Animal models using vaccines targeting oxidized LDL or ApoB have shown reduced plaque burden, improved stability, and decreased inflammatory markers—supporting translational potential.</P></DIV>\n    <DIV><H3>Human Clinical Development</H3><P>Early-phase trials are underway to evaluate safety and immunogenicity of candidate vaccines; larger efficacy studies will determine if they can reduce cardiovascular events in high-risk populations.</P></DIV>\n    <DIV><H3>Challenges Ahead</H3><P>Key hurdles include antigen selection, optimal adjuvant use, patient stratification based on immune profile, and ensuring long-term tolerance without unintended autoimmunity or excessive inflammation.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background9.jpg" alt="背景图：动脉粥样硬化疫苗策略示意图，突出其通过诱导免疫耐受来减少斑块形成的作用机制" background="true" />\n</SECTION>\n<!-- 第10页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:43.678418+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '8d2583f4-46e6-489b-bcff-554faccede14', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第11页开始-->\n<SECTION layout="staircase" page_number=11>\n  <H1>Regulatory T Cell Therapy for Immune Modulation in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Role of Tregs in Vascular Immune Homeostasis</H3><P>Regulatory T cells (Tregs) maintain immune tolerance by suppressing effector T cell responses and producing anti-inflammatory cytokines like IL-10 and TGF-β—critical for preventing excessive inflammation in arterial walls.</P></DIV>\n    <DIV><H3>Treg Deficiency in Advanced Disease</H3><P>In atherosclerotic plaques, Treg numbers are often reduced or functionally impaired, leading to unchecked pro-inflammatory activity from Th1 and Th17 cells—contributing to plaque progression and instability.</P></DIV>\n    <DIV><H3>Therapeutic Strategies to Boost Tregs</H3><P>Approaches include adoptive transfer of ex vivo expanded Tregs, pharmacological expansion using low-dose IL-2, and targeting pathways such as CTLA-4 or FOXP3 to enhance Treg stability and function.</P></DIV>\n    <DIV><H3>Preclinical Evidence</H3><P>Animal models show that increasing Treg levels reduces plaque burden, enhances fibrous cap thickness, and decreases inflammatory markers—demonstrating potential for clinical translation.</P></DIV>\n    <DIV><H3>Challenges and Future Directions</H3><P>Key challenges include ensuring long-term Treg survival in the inflammatory plaque environment, avoiding unintended immunosuppression, and identifying optimal patient populations for targeted therapy.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background10.jpg" alt="背景图：调节性T细胞（Treg）在动脉粥样硬化中通过抑制炎症和促进斑块稳定的作用示意图，突出其作为免疫调节治疗靶点的潜力" background="true" />\n</SECTION>\n<!-- 第11页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:06:51.771321+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'd940f4fc-52be-4560-b8ad-ba8b9feeda62', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第12页开始-->\n<SECTION layout="staircase" page_number=12>\n  <H1>Future Directions and Challenges in Cardiovascular Immunotherapy</H1>\n\n  <STAIRCASE>\n    <DIV><H3>Identifying Novel Immune Targets for Therapy</H3><P>Emerging research highlights new players such as specific cytokines (e.g., IL-6, IL-18), inflammasome components (NLRP3), and regulatory T cell pathways that may offer precise immunomodulatory opportunities beyond current targets like IL-1β.</P></DIV>\n    <DIV><H3>Translational Challenges from Bench to Bedside</H3><P>Preclinical models often fail to fully capture human immune complexity or plaque heterogeneity—highlighting the need for better biomarkers, improved animal models, and robust clinical trial designs tailored to immune endpoints.</P></DIV>\n    <DIV><H3>Personalized Immunotherapy Approaches</H3><P>Integration of genomics, immune profiling, and disease stage could enable patient-specific strategies—such as selecting therapies based on dominant immune phenotypes (e.g., Th1 vs. Treg bias) or inflammatory burden.</P></DIV>\n    <DIV><H3>Long-Term Safety and Efficacy Evaluation</H3><P>Chronic immune modulation risks include infection, malignancy, or paradoxical autoimmunity—requiring long-term follow-up in diverse populations to ensure sustained benefit without unintended consequences.</P></DIV>\n    <DIV><H3>Combination Therapies: Synergy with Traditional Treatments</H3><P>Future regimens may combine immunotherapy with statins, PCSK9 inhibitors, or lifestyle interventions—potentially amplifying plaque stabilization and reducing residual cardiovascular risk beyond lipid control alone.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background11.jpg" alt="背景图：动脉粥样硬化免疫治疗未来方向示意图，突出个性化、精准化和长期安全评估的挑战与机遇" background="true" />\n</SECTION>\n<!-- 第12页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:00.218272+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'e6e62997-56aa-4508-915b-af18de02fdc8', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第13页开始-->\n<SECTION layout="staircase" page_number=13>\n  <H1>Emerging Immune Targets and Therapeutic Strategies in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>IL-6 and NLRP3 Inflammasome: New Frontiers</H3><P>Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase response, leukocyte activation, and endothelial dysfunction—linked to plaque instability and cardiovascular events.</P></DIV>\n    <DIV><H3>Targeting IL-6</H3><P>Monoclonal antibodies like tocilizumab (anti-IL-6R) have shown efficacy in rheumatoid arthritis; ongoing studies assess their impact on atherosclerotic inflammation and CVD outcomes.</P></DIV>\n    <DIV><H3>NLRP3 Inflammasome Activation</H3><P>The NLRP3 inflammasome senses danger signals (e.g., cholesterol crystals, oxidized LDL), triggering caspase-1-mediated maturation of IL-1β—a key driver of plaque progression.</P></DIV>\n    <DIV><H3>Therapeutic Inhibition</H3><P>Pharmacological inhibitors of NLRP3 (e.g., MCC950) reduce lesion burden and inflammation in preclinical models—representing a promising upstream target for immunomodulation.</P></DIV>\n    <DIV><H3>CCL2/CCR2 Axis: Cell Recruitment Pathway</H3><P>Chemokine receptor CCR2 mediates monocyte trafficking into plaques via binding to CCL2 (MCP-1); blocking this axis reduces early lesion formation in animal models.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background12.jpg" alt="背景图：动脉粥样硬化中新兴免疫靶点（如IL-6、NLRP3、CCL2/CCR2）的示意图，突出其在炎症驱动和细胞募集中的作用" background="true" />\n</SECTION>\n<!-- 第13页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:10.647115+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '9bf24dd6-f17d-4119-a939-b43f48f19fca', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第14页开始-->\n<SECTION layout="staircase" page_number=14>\n  <H1>Emerging Immune Targets and Therapeutic Strategies in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>IL-6 and NLRP3 Inflammasome: New Frontiers</H3><P>Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase response, leukocyte activation, and endothelial dysfunction—linked to plaque instability and cardiovascular events.</P></DIV>\n    <DIV><H3>Targeting IL-6</H3><P>Monoclonal antibodies like tocilizumab (anti-IL-6R) have shown efficacy in rheumatoid arthritis; ongoing studies assess their impact on atherosclerotic inflammation and CVD outcomes.</P></DIV>\n    <DIV><H3>NLRP3 Inflammasome Activation</H3><P>The NLRP3 inflammasome senses danger signals (e.g., cholesterol crystals, oxidized LDL), triggering caspase-1-mediated maturation of IL-1β—a key driver of plaque progression.</P></DIV>\n    <DIV><H3>Therapeutic Inhibition</H3><P>Pharmacological inhibitors of NLRP3 (e.g., MCC950) reduce lesion burden and inflammation in preclinical models—representing a promising upstream target for immunomodulation.</P></DIV>\n    <DIV><H3>CCL2/CCR2 Axis: Cell Recruitment Pathway</H3><P>Chemokine receptor CCR2 mediates monocyte trafficking into plaques via binding to CCL2 (MCP-1); blocking this axis reduces early lesion formation in animal models.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background12.jpg" alt="背景图：动脉粥样硬化中新兴免疫靶点（如IL-6、NLRP3、CCL2/CCR2）的示意图，突出其在炎症驱动和细胞募集中的作用" background="true" />\n</SECTION>\n<!-- 第14页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:19.769668+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '020f4b96-0098-468b-9527-be891043a0f1', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第14页开始-->\n<SECTION layout="columns" page_number=14>\n  <H1>Emerging Immune Targets and Therapeutic Strategies in Atherosclerosis</H1>\n\n  <COLUMNS>\n    <DIV>\n      <H3>IL-6 and NLRP3 Inflammasome: New Frontiers</H3>\n      <P>Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase response, leukocyte activation, and endothelial dysfunction—linked to plaque instability and cardiovascular events.</P>\n      <P>Targeting IL-6 with monoclonal antibodies like tocilizumab (anti-IL-6R) has shown efficacy in rheumatoid arthritis; ongoing studies assess their impact on atherosclerotic inflammation and CVD outcomes.</P>\n    </DIV>\n    \n    <DIV>\n      <H3>NLRP3 Inflammasome Activation</H3>\n      <P>The NLRP3 inflammasome senses danger signals (e.g., cholesterol crystals, oxidized LDL), triggering caspase-1-mediated maturation of IL-1β—a key driver of plaque progression.</P>\n      <P>Pharmacological inhibitors of NLRP3 (e.g., MCC950) reduce lesion burden and inflammation in preclinical models—representing a promising upstream target for immunomodulation.</P>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background13.jpg" alt="背景图：动脉粥样硬化中新兴免疫靶点（如IL-6、NLRP3）的示意图，突出其在炎症驱动和细胞募集中的作用" background="true" />\n</SECTION>\n<!-- 第14页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:28.277501+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'fefee33d-7676-4f64-a625-17b553ef0100', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第14页开始-->\n<SECTION layout="arrows" page_number=14>\n  <H1>Challenges in Translating Immune Therapies to Clinical Practice</H1>\n\n  <ARROWS>\n    <DIV><H3>Preclinical Limitations</H3><P>Animal models often fail to fully replicate human immune complexity, plaque heterogeneity, or comorbid conditions like diabetes and chronic kidney disease—limiting predictive value for clinical outcomes.</P></DIV>\n    <DIV><H3>Target Heterogeneity</H3><P>Immune responses vary significantly between individuals based on genetics, age, sex, microbiome, and disease stage—making universal therapeutic strategies difficult to implement.</P></DIV>\n    <DIV><H3>Endpoint Selection</H3><P>Defining meaningful clinical endpoints beyond major adverse cardiovascular events (MACE) is crucial—for example, plaque regression, inflammatory biomarker reduction, or immune cell profiling changes—to better capture immunomodulatory effects.</P></DIV>\n    <DIV><H3>Long-Term Safety Concerns</H3><P>Chronic immune modulation may increase risks of infection, malignancy, or paradoxical autoimmunity—requiring rigorous long-term monitoring in diverse patient populations.</P></DIV>\n  </ARROWS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background13.jpg" alt="背景图：动脉粥样硬化免疫治疗从实验室到临床转化中的挑战示意图，突出动物模型局限性、个体差异和长期安全性问题" background="true" />\n</SECTION>\n<!-- 第14页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:36.951957+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '45d31520-b433-481e-8721-6d34f4593045', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第15页开始-->\n<SECTION layout="staircase" page_number=15>\n  <H1>Emerging Immune Targets and Therapeutic Strategies in Atherosclerosis</H1>\n\n  <STAIRCASE>\n    <DIV><H3>IL-6 and NLRP3 Inflammasome: New Frontiers</H3><P>Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase response, leukocyte activation, and endothelial dysfunction—linked to plaque instability and cardiovascular events.</P></DIV>\n    <DIV><H3>Targeting IL-6</H3><P>Monoclonal antibodies like tocilizumab (anti-IL-6R) have shown efficacy in rheumatoid arthritis; ongoing studies assess their impact on atherosclerotic inflammation and CVD outcomes.</P></DIV>\n    <DIV><H3>NLRP3 Inflammasome Activation</H3><P>The NLRP3 inflammasome senses danger signals (e.g., cholesterol crystals, oxidized LDL), triggering caspase-1-mediated maturation of IL-1β—a key driver of plaque progression.</P></DIV>\n    <DIV><H3>Therapeutic Inhibition</H3><P>Pharmacological inhibitors of NLRP3 (e.g., MCC950) reduce lesion burden and inflammation in preclinical models—representing a promising upstream target for immunomodulation.</P></DIV>\n    <DIV><H3>CCL2/CCR2 Axis: Cell Recruitment Pathway</H3><P>Chemokine receptor CCR2 mediates monocyte trafficking into plaques via binding to CCL2 (MCP-1); blocking this axis reduces early lesion formation in animal models.</P></DIV>\n  </STAIRCASE>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background12.jpg" alt="背景图：动脉粥样硬化中新兴免疫靶点（如IL-6、NLRP3、CCL2/CCR2）的示意图，突出其在炎症驱动和细胞募集中的作用" background="true" />\n</SECTION>\n<!-- 第15页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:07:59.038892+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '0001e279-5f87-411d-931c-ef324f816061', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第15页开始-->\n<SECTION layout="columns" page_number=15>\n  <H1>Emerging Immune Targets and Therapeutic Strategies in Atherosclerosis</H1>\n\n  <COLUMNS>\n    <DIV>\n      <H3>IL-6 and NLRP3 Inflammasome: New Frontiers</H3>\n      <P>Interleukin-6 (IL-6) is a pleiotropic cytokine involved in acute-phase response, leukocyte activation, and endothelial dysfunction—linked to plaque instability and cardiovascular events.</P>\n      <P>Monoclonal antibodies like tocilizumab (anti-IL-6R) have shown efficacy in rheumatoid arthritis; ongoing studies assess their impact on atherosclerotic inflammation and CVD outcomes.</P>\n    </DIV>\n    \n    <DIV>\n      <H3>NLRP3 Inflammasome Activation</H3>\n      <P>The NLRP3 inflammasome senses danger signals (e.g., cholesterol crystals, oxidized LDL), triggering caspase-1-mediated maturation of IL-1β—a key driver of plaque progression.</P>\n      <P>Pharmacological inhibitors of NLRP3 (e.g., MCC950) reduce lesion burden and inflammation in preclinical models—representing a promising upstream target for immunomodulation.</P>\n    </DIV>\n  </COLUMNS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background14.jpg" alt="背景图：动脉粥样硬化中新兴免疫靶点（如IL-6、NLRP3）的示意图，突出其在炎症驱动和细胞募集中的作用" background="true" />\n</SECTION>\n<!-- 第15页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:20.903476+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '69d3ce26-0f0f-404e-a8db-62bf685783d8', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第15页开始-->\n<SECTION layout="pyramid" page_number=15>\n  <H1>Personalized Immunotherapy Approaches in Atherosclerosis</H1>\n\n  <PYRAMID>\n    <DIV><H3>Foundation: Immune Profiling</H3><P>Integration of genomics, proteomics, and immune cell phenotyping to identify patient-specific inflammatory signatures—e.g., Th1 bias, Treg deficiency, or NET burden.</P></DIV>\n    <DIV><H3>Strategy: Targeted Intervention</H3><P>Matching immune phenotype with appropriate therapy—e.g., IL-1β inhibition for high IL-1β activity, Treg expansion for low regulatory tone, or NET degradation in neutrophil-dominant inflammation.</P></DIV>\n    <DIV><H3>Outcome: Precision Modulation</H3><P>Maximizing therapeutic benefit while minimizing off-target effects—tailoring immunomodulation to individual disease stage, comorbidities (e.g., diabetes), and genetic risk factors.</P></DIV>\n  </PYRAMID>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background14.jpg" alt="背景图：动脉粥样硬化个性化免疫治疗金字塔示意图，突出从免疫分型到精准干预的层级逻辑" background="true" />\n</SECTION>\n<!-- 第15页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:35.095582+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '458235c9-749a-4e14-b36f-6974794c706d', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第16页开始-->\n<SECTION layout="vertical" page_number=16>\n  <H1>Conclusion and Future Outlook: The Era of Cardiovascular Immunotherapy</H1>\n\n  <BULLETS>\n    <DIV><H3>Paradigm Shift in Atherosclerosis Management</H3><P>Atherosclerosis is now understood as a chronic inflammatory disease—not just a lipid disorder—opening doors for immune-targeted therapies that go beyond traditional risk factor control.</P></DIV>\n    <DIV><H3>Proven Therapeutic Potential</H3><P>Clinical trials like CANTOS have demonstrated that targeting specific inflammatory pathways (e.g., IL-1β) reduces cardiovascular events independently of lipid-lowering, validating immunomodulation as a viable strategy.</P></DIV>\n    <DIV><H3>Emerging Targets and Precision Approaches</H3><P>New frontiers include NLRP3 inflammasome inhibition, NET degradation, personalized Treg therapy, and antigen-specific vaccines—all poised to transform how we treat and prevent atherosclerosis.</P></DIV>\n    <DIV><H3>Challenges Ahead</H3><P>Key hurdles remain: improving translational models, defining optimal biomarkers, ensuring long-term safety, and integrating immunotherapy with existing treatments like statins and PCSK9 inhibitors.</P></DIV>\n    <DIV><H3>Looking Forward</H3><P>The future lies in precision cardiovascular immunology—tailoring interventions to individual immune profiles, plaque phenotypes, and comorbidities—to achieve maximal benefit with minimal risk.</P></DIV>\n  </BULLETS>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background15.jpg" alt="背景图：动脉粥样硬化免疫治疗未来展望示意图，突出精准医学与多靶点联合治疗的前景" background="true" />\n</SECTION>\n<!-- 第16页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:42.939859+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '50b17546-630c-44a9-b993-4c6c1e7a1bbb', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:42.952455+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '98b56781-d74d-4e23-ab50-00b5246095a3', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第16页开始-->\n<SECTION layout="pyramid" page_number=16>\n  <H1>Conclusion: Integrating Immune Insights into Cardiovascular Care</H1>\n\n  <PYRAMID>\n    <DIV><H3>Foundation: Inflammation as a Core Driver</H3><P>Atherosclerosis is no longer viewed solely as a lipid disorder—it is now understood as a chronic inflammatory disease where immune mechanisms orchestrate plaque initiation, progression, and rupture.</P></DIV>\n    <DIV><H3>Strategy: Targeted Immunomodulation</H3><P>Emerging therapies such as IL-1β inhibition (canakinumab), Treg expansion, NET degradation, and antigen-specific vaccination offer precise tools to modulate harmful inflammation while preserving protective immunity.</P></DIV>\n    <DIV><H3>Outcome: Personalized, Precision Cardiovascular Medicine</H3><P>By integrating immune profiling with clinical risk assessment, we can move toward tailored immunotherapies that reduce residual cardiovascular risk beyond traditional lipid-lowering strategies—ushering in a new era of precision cardiology.</P></DIV>\n  </PYRAMID>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background15.jpg" alt="背景图：动脉粥样硬化免疫机制与治疗整合示意图，突出从炎症基础到个性化精准治疗的转化路径" background="true" />\n</SECTION>\n<!-- 第16页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:50.519761+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'b4b02436-8a5a-4d3d-846d-b61c22e2425e', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:50.533881+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'aaf7460b-0cec-4f14-96bf-1591180b0a1e', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第16页开始-->\n<SECTION layout="pyramid" page_number=16>\n  <H1>Conclusion: Integrating Immune Insights into Cardiovascular Care</H1>\n\n  <PYRAMID>\n    <DIV><H3>Foundation: Inflammation as a Core Driver</H3><P>Atherosclerosis is no longer viewed solely as a lipid disorder—it is now understood as a chronic inflammatory disease where immune mechanisms orchestrate plaque initiation, progression, and rupture.</P></DIV>\n    <DIV><H3>Strategy: Targeted Immunomodulation</H3><P>Emerging therapies such as IL-1β inhibition (canakinumab), Treg expansion, NET degradation, and antigen-specific vaccination offer precise tools to modulate harmful inflammation while preserving protective immunity.</P></DIV>\n    <DIV><H3>Outcome: Personalized, Precision Cardiovascular Medicine</H3><P>By integrating immune profiling with clinical risk assessment, we can move toward tailored immunotherapies that reduce residual cardiovascular risk beyond traditional lipid-lowering strategies—ushering in a new era of precision cardiology.</P></DIV>\n  </PYRAMID>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background15.jpg" alt="背景图：动脉粥样硬化免疫机制与治疗整合示意图，突出从炎症基础到个性化精准治疗的转化路径" background="true" />\n</SECTION>\n<!-- 第16页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:51.052739+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': 'b6571df1-19d2-4534-9b3c-8a0b4276c241', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:51.067969+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '5eaccd18-539b-4cc7-89cc-7a09d376256f', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '<!-- 第16页开始-->\n<SECTION layout="pyramid" page_number=16>\n  <H1>Conclusion: Integrating Immune Insights into Cardiovascular Care</H1>\n\n  <PYRAMID>\n    <DIV><H3>Foundation: Inflammation as a Core Driver</H3><P>Atherosclerosis is no longer viewed solely as a lipid disorder—it is now understood as a chronic inflammatory disease where immune mechanisms orchestrate plaque initiation, progression, and rupture.</P></DIV>\n    <DIV><H3>Strategy: Targeted Immunomodulation</H3><P>Emerging therapies such as IL-1β inhibition (canakinumab), Treg expansion, NET degradation, and antigen-specific vaccination offer precise tools to modulate harmful inflammation while preserving protective immunity.</P></DIV>\n    <DIV><H3>Outcome: Personalized, Precision Cardiovascular Medicine</H3><P>By integrating immune profiling with clinical risk assessment, we can move toward tailored immunotherapies that reduce residual cardiovascular risk beyond traditional lipid-lowering strategies—ushering in a new era of precision cardiology.</P></DIV>\n  </PYRAMID>\n\n  <IMG src="https://infoxmed20.infox-med.com/ppt_background15.jpg" alt="背景图：动脉粥样硬化免疫机制与治疗整合示意图，突出从炎症基础到个性化精准治疗的转化路径" background="true" />\n</SECTION>\n<!-- 第16页结束-->'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:51.583519+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}, {'type': 'data', 'text': {'id': '716606cace124a17aa4bc6709151a501', 'jsonrpc': '2.0', 'result': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'final': False, 'kind': 'status-update', 'status': {'message': {'contextId': '6c4c100a-add6-4e63-802a-77c45436973f', 'kind': 'message', 'messageId': '20a4e5c9-6451-45cf-b50f-4c223a58def1', 'metadata': {'author': 'PPTWriterSubAgent', 'show': True, 'references': []}, 'parts': [{'kind': 'text', 'text': '\n</PRESENTATION>```'}], 'role': 'agent', 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}, 'state': 'working', 'timestamp': '2025-08-01T02:08:51.598733+00:00'}, 'taskId': '460f34a6-0355-4c60-88b7-7f2f51f34255'}}}]
    # 用于存储每个页码对应的XML内容，键为页码，值为XML字符串
    page_xml_map = {}

    # 用于存储 <PRESENTATION> 和 </PRESENTATION> 这类非页码部分的XML
    overall_start_xml = ""
    overall_end_xml = ""

    # 存储最新的references
    latest_references = []

    # 正则表达式用于从 <SECTION> 标签中提取 page_number 属性
    # pattern = re.compile(r'<SECTION[^>]*page_number=(\d+)[^>]*>')
    # 改进的正则表达式，以匹配 page_number="1" 或 page_number=1 等多种情况
    # 同时确保只匹配 <SECTION ...> 标签中的 page_number
    # [^>]* 匹配除了 > 之外的任何字符，0次或多次
    # page_number=(\d+|"\d+") 匹配 page_number=数字 或 page_number="数字"
    page_number_pattern = re.compile(r'<SECTION[^>]+page_number\s*=\s*["\']?(\d+)["\']?[^>]*>')

    for one in Stream:
        # 提取 XML 文本内容
        content_parts = one["text"]["result"]["status"]["message"]["parts"]
        text_content = content_parts[0]["text"]

        # --- 移除 Markdown XML block 分隔符 ---
        start_delimiter = "```xml\n"
        end_delimiter = "```"
        if text_content.startswith(start_delimiter):
            text_content = text_content[len(start_delimiter):]
        if text_content.endswith(end_delimiter):
            text_content = text_content[:-len(end_delimiter)]

        # 移除 XML 注释行，例如 <!-- 第1页开始-->
        text_content = re.sub(r'<!--.*?-->\n?', '', text_content)

        # 更新 references，始终保留最新的
        latest_references = one["text"]["result"]["status"]["message"]["metadata"]["references"]

        # 尝试匹配 page_number
        match = page_number_pattern.search(text_content)

        if match:
            # 如果找到 page_number，则将其作为键存储，值是整个 SECTION 块的 XML
            page_number = int(match.group(1))
            page_xml_map[page_number] = text_content.strip()  # .strip() 移除多余的空白行
        elif text_content.strip() == '<PRESENTATION>':
            overall_start_xml = text_content.strip()
        elif text_content.strip() == '</PRESENTATION>':
            overall_end_xml = text_content.strip()

    # 按照页码顺序拼接最终的 XML 内容
    final_xml_parts = []

    if overall_start_xml:
        final_xml_parts.append(overall_start_xml)

    # 获取所有页码，并进行排序
    sorted_page_numbers = sorted(page_xml_map.keys())

    for page_num in sorted_page_numbers:
        final_xml_parts.append(page_xml_map[page_num])

    if overall_end_xml:
        final_xml_parts.append(overall_end_xml)

    PPT_content = "\n".join(final_xml_parts)  # 使用换行符连接各部分，保持可读性

    return PPT_content, latest_references

def parse_div(div):
    children = []
    for elem in div:
        if elem.tag == "H3":
            try:
                children.append({
                    "type": "h3",
                    "children": [{"text": elem.text.strip()}]
                })
            except Exception as e:
                logger.error(f"当前处理: div.elem.tag == h3 出错, 报错信息: \n{e}")
        elif elem.tag == "P":
            try:
                children.append({
                    "type": "p",
                    "children": [{"text": elem.text.strip()}]
                })
            except Exception as e:
                logger.error(f"当前处理: div.elem.tag == P 出错, 报错信息: \n{e}")
    return {
        "type": "bullet",
        "children": children
    }

# 解析每个 SECTION 页面
def parse_section(section):
    result = {
        "id": str(uuid.uuid4()),
        "content": [],
        "rootImage": None,
        "layoutType": section.attrib.get("layout", "vertical"),
        "alignment": "center"
    }

    # H1 标题
    h1 = section.find("H1")
    if h1 is not None:
        result["content"].append({
            "type": "h1",
            "children": [{"text": h1.text.strip()}]
        })

    # 支持的结构体标签
    structured_tags = ["BULLETS", "COLUMNS", "STAIRCASE", "TIMELINE"]
    for tag in structured_tags:
        node = section.find(tag)
        if node is not None:
            bullets = []
            for div in node.findall("DIV"):
                try:
                    bullets.append(parse_div(div))
                except Exception as e:
                    logger.error(f"解析div标签出错: \n{e}")
            result["content"].append({
                "type": "bullets",
                "children": bullets
            })

    # 图片
    img = section.find("IMG")
    if img is not None:
        result["rootImage"] = {
            "url": img.attrib.get("src", ""),
            "query": "",
            "background": img.attrib.get("background", "false").lower() == "true",
            "alt": img.attrib.get("alt", "")
        }

    return result


def generate_pptx_file(title, sections, references):
    front_data = {
        "title": title,
        "sections": sections,
        "references": references
    }
    download_url = os.environ["DOWNLOAD_URL"]
    response = requests.post(f"{download_url}/generate-ppt", json=front_data, timeout=120)  # 增加超时时间
    print(f"Status Code: {response.status_code}")
    response_json = response.json()
    print(f"Response Body: {response_json}")
    assert "ppt_url" in response_json, "PPT URL没有在结果中出现，请检查"
    assert response_json["ppt_url"].endswith(".pptx")
    ppt_url = response_json["ppt_url"]
    return ppt_url

def parse_trunk_data(trunk_list, references, title):
    """

    :param trunks: 大模型生成的结果,列表
    :return:
    """
    # 用于存储每个页码对应的XML内容，键为页码，值为XML字符串
    page_xml_map = {}

    # 用于存储 <PRESENTATION> 和 </PRESENTATION> 这类非页码部分的XML
    overall_start_xml = ""
    overall_end_xml = ""

    # 存储最新的references
    latest_references = []

    # 正则表达式用于从 <SECTION> 标签中提取 page_number 属性
    # pattern = re.compile(r'<SECTION[^>]*page_number=(\d+)[^>]*>')
    # 改进的正则表达式，以匹配 page_number="1" 或 page_number=1 等多种情况
    # 同时确保只匹配 <SECTION ...> 标签中的 page_number
    # [^>]* 匹配除了 > 之外的任何字符，0次或多次
    # page_number=(\d+|"\d+") 匹配 page_number=数字 或 page_number="数字"
    page_number_pattern = re.compile(r'<SECTION[^>]+page_number\s*=\s*["\']?(\d+)["\']?[^>]*>')

    for one in trunk_list:
        # 提取 XML 文本内容
        content_parts = one["text"]["result"]["status"]["message"]["parts"]
        text_content = content_parts[0]["text"]

        # --- 移除 Markdown XML block 分隔符 ---
        start_delimiter = "```xml\n"
        end_delimiter = "```"
        if text_content.startswith(start_delimiter):
            text_content = text_content[len(start_delimiter):]
        if text_content.endswith(end_delimiter):
            text_content = text_content[:-len(end_delimiter)]

        # 移除 XML 注释行，例如 <!-- 第1页开始-->
        text_content = re.sub(r'<!--.*?-->\n?', '', text_content)

        # 更新 references，始终保留最新的
        latest_references = one["text"]["result"]["status"]["message"]["metadata"]["references"]

        # 尝试匹配 page_number
        match = page_number_pattern.search(text_content)

        if match:
            # 如果找到 page_number，则将其作为键存储，值是整个 SECTION 块的 XML
            page_number = int(match.group(1))
            page_xml_map[page_number] = text_content.strip()  # .strip() 移除多余的空白行
        elif text_content.strip() == '<PRESENTATION>':
            overall_start_xml = text_content.strip()
        elif text_content.strip() == '</PRESENTATION>':
            overall_end_xml = text_content.strip()

    # 按照页码顺序拼接最终的 XML 内容
    final_xml_parts = []

    if overall_start_xml:
        final_xml_parts.append(overall_start_xml)

    # 获取所有页码，并进行排序
    sorted_page_numbers = sorted(page_xml_map.keys())

    for page_num in sorted_page_numbers:
        final_xml_parts.append(page_xml_map[page_num])

    if overall_end_xml:
        final_xml_parts.append(overall_end_xml)

    PPT_content = "\n".join(final_xml_parts)  # 使用换行符连接各部分，保持可读性
    try:
        soup = BeautifulSoup(PPT_content, "xml")  # 或 "html.parser" 更宽松
        clean_xml = str(soup)  # 转换为良好结构的 XML 字符串
        parser = ET.XMLParser()
        root = ET.fromstring(clean_xml, parser=parser)
        sections = root.findall("SECTION")
        # sections_data = [parse_section(sec) for sec in sections]
        sections_data = []
        for sec in sections:
            try:
                sections_data.append(parse_section(sec))
            except Exception as e:
                logger.error(f"XML解析错误: {e}\n\n 出错内容为:\n*************************************************************************************************\n\n{sec}\n\n*************************************************************************************************")
    except Exception as e:
        print(f"XML解析错误: {e}")
        logger.error(f"XML解析错误: {e}")
    # 输出 JSON（格式化）
    print(json.dumps(sections_data, ensure_ascii=False, indent=2))
    ppt_url = generate_pptx_file(title=title,sections=sections_data, references=references)
    return ppt_url

def main_test_parse_xml():
    # 解析主结构
    # xml_data, references = generate_ppt_xml()
    xml_data, references = generate_ppt_xml_third()
    title = "Cart-T cell research"
    soup = BeautifulSoup(xml_data, "xml")  # 或 "html.parser" 更宽松
    clean_xml = str(soup)  # 转换为良好结构的 XML 字符串
    parser = ET.XMLParser()
    root = ET.fromstring(clean_xml, parser=parser)
    sections = root.findall("SECTION")
    sections_data = [parse_section(sec) for sec in sections]
    # 输出 JSON（格式化）
    print(json.dumps(sections_data, ensure_ascii=False, indent=2))
    ppt_url = generate_pptx_file(title=title,sections=sections_data, references=references)
    print(f"生成的ppt_url是: {ppt_url}")
    return ppt_url

if __name__ == '__main__':
    main_test_parse_xml()